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ABSTRACT 
Though death rates due to traumatic brain injury (TBI) are decreasing in the United Statues, TBI 
remains a significant public health problem. Individuals who survive moderate and severe TBI 
become at risk of developing secondary complications, including post-traumatic seizures (PTS). 
PTS are well-recognized sequelae of TBI. Despite previous research, there remains a high degree 
of variability in who will develop PTS and no approved prophylactic medications to prevent late 
PTS exist. Late PTS is associated with significant morbidity and worse outcomes following TBI. 
Therefore, it is of public health importance to understand the characteristics of individuals with 
PTS, identify factors to improve prognostication, and explore novel risk factors to support a 
personalized medicine approach.  
Using the Traumatic Brain Injury Model Systems, we examined the incidence of 
immediate (<24hours), early (1–7 days), and late (>7 days post-injury) PTS. Incidence of new 
onset seizures was highest immediately (8.9%) and one-year (9.2%) post-injury. Late PTS 
prevalence surpassed 20% at five-years post-injury. Incidence was stratified by potential risk 
factors and relative risk calculated. Individuals with immediate but not early seizures had a 
significantly greater incidence of late PTS compared to individuals not seizing during acute 
hospitalization.  
We then developed and internally validated prognostic models for PTS during acute 
hospitalization, at one-year, and two-years post-TBI. We identified multiple variables, including 
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novel factors such as pre-injury mental health conditions, predictive of PTS. Year one and two 
models showed fair-to-good ability to discriminate PTS, supporting the idea that more accurate 
prognostication of late PTS can be accomplished.  
Lastly, we examined genetic variation in neuronal glutamate transporter genes as risk 
factors for PTS. We identified genetic variants significantly associated with increased PTS risk, 
after controlling for known risk factors. The relative effect size of the genetic markers suggests 
these variants may be significant predictors of PTS and may improve prognostic model 
reliability and validity. 
Classifying subpopulations at high-risk for PTS could facilitate research regarding the 
effectiveness of tiered prophylaxis and novel pharmacological interventions, improving 
prevention and treatment. Together, findings from the current work may affect future research 
and programmatic decisions, positively impacting those at risk for PTS.
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1.0  INTRODUCTION 
Traumatic brain injury (TBI) is a significant public health concern and is a major cause of 
morbidity and mortality, especially to those under age 45, in the United States 1; 2. TBI is 
extremely heterogeneous regarding mechanism of injury, injury severity, and possible outcome. 
Individuals may experience many different complications and comorbidities associated with TBI 
that may continue chronically, persisting for many years or even throughout the lifetime 
following injury3-5.  
Individuals with more severe injury are particularly affected by chronic conditions 
associated with TBI. Among individuals who survive a severe TBI, disability rates are estimated 
as high as 77% 6. Chronic complications include, but are not limited to, poor functional outcome, 
decreased cognitive function, psychosocial and/or behavioral problems, decreased general health, 
and other neurological sequelae. These complications contribute substantially to the cost of care 
associated with TBI, which is estimated at more than $60 billion annually in the United States 7. 
Lifetime total cost of care is estimated to exceed $1.8 million for an individual 7. In addition to 
medical cost incurred, TBI may significantly increase years of potential life lost and decrease 
quality of life.  
Post-traumatic seizures (PTS) are a well-recognized sequela of traumatic brain. PTS have 
been documented as a common complication of TBI for decades. Incidence of PTS varies 
drastically throughout the literature and is dependent on many factors including study design and 
 2 
characteristics of the study population. As incidence of TBI increases and death due to TBI 
decreases, more individuals will be at risk of developing and living with chronic complications. 
It can also be expected that PTS incidence will increase. Previously, seizure prophylaxis has 
been shown to be effective in reducing the incidence of PTS in the first week after injury, but has 
no long-term benefit (Temkin, 1990). Current recommendations from the American Academy of 
Neurology and the Brain Trauma Foundation include delivery of phenytoin for seizure 
prophylaxis during the first seven days post-TBI 8; 9. Yet, despite decades of research, there are 
no effective pharmacological interventions to prevent post-traumatic seizures that develop after 
seven days post-injury and, it does not appear that rates of PTS are decreasing. Increasingly, 
novel risk factors for PTS and mechanisms of epileptogenesis following TBI are being 
investigated to identify potential new targets for therapeutic treatment.  
1.1 TRAUMATIC BRAIN INJURY 
1.1.1 Definitions 
Traumatic brain injury is caused by an impact to the head from an external force that disrupts 
physiological function. External forces can include direct mechanical impact (i.e. blunt trauma), 
acceleration or deceleration associated injury (i.e. whiplash), blast injury caused by a pressure 
wave (i.e. explosion), or penetrating injury (i.e. gunshot). 
Severity of TBI can be classified multiple ways. Originally developed to classify levels of 
consciousness 10, the Glasgow Coma Scale (GCS) has become the most widely used tool to 
describe TBI severity. The GCS score ranges from 3 to 15: 3-8 indicating severe, 9-12 indicating 
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moderate, and 13-15 indicating mild TBI 11. Alternative criteria based on loss of consciousness 
and post-traumatic amnesia are also used 12. Many organizations, including the Department of 
Defense (DoD), Veterans Affairs (VA), and Centers for Disease Control and Prevention (CDC), 
continue to utilize a combination of clinical variables to assess TBI severity (Table 1). 
Table 1. Classification of Traumatic Brain Injury 
Criteria Mild Moderate Severe 
Structural Imaging1 Normal Normal or abnormal Normal or abnormal 
Loss of Consciousness 0 - 30 min > 30 min but < 24 hours > 24 hours 
Alteration of 
Consciousness2 0 - 24 hours > 24 hours  
Post-Traumatic 
Amnesia ≤ 24 hours 24 hours – 7 days > 7 days 
Glasgow Coma Scale3 13 – 15 9 – 12 3 - 8 
1Abnormalities not related to trauma may be present with mild injury;  
2Classification of severe injury not made based on alteration of consciousness alone; 
3Typically based on best GCS score is first 24 hours post-injury 
*adapted from Silver, McAllister, & Yudofsky. Textbook of Traumatic Brain Injury, Second 
Edition 
 
In addition to severity, TBI is often classified as closed-head or penetrating brain injury. 
Many studies within the existing literature categorize TBI into one of four classifications: mild, 
moderate, severe, or penetrating. Despite the fact that it is possible to obtain a GCS score on an 
individual with a penetrating TBI (pTBI), researchers and clinicians often refer to pTBI as a 
distinct category.  
As medical care has evolved, and computed topography (CT) became a part of standard 
care, neuroradiological findings have increasingly been used to differentiate and define TBI. 
Abnormalities detected via CT are categorized based on location and type of injury [i.e. which 
hemisphere, brain region, and pathology present (Table 2)]. Advances in neuroradiological 
imaging through tools such as magnetic resonance imaging (MRI), positron emission topography 
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(PET), and magnetic resonance spectroscopy (MRS), may provide additional ways to classify 
and differentiate brain injury. Some definitions regarding severity of TBI include positive 
evidence of abnormal pathology via CT imaging as a distinguishing characteristic.  
Table 2. Abnormal Pathologies Identified via Computed Tomography 
Variable Definition 
Intracranial 
Hemorrhage (ICH) 
Bleeding within the skull (cranium) 
Contusion Area(s) of bleeding on the surface of the brain, most commonly along 
the undersurface and poles of the frontal and temporal lobes 
Subdural Hematoma 
(SDH) 
Presence of extra-axial blood clot or collection within sub-dural space, 
between surface of the brain and dura matter 
Subarachnoid 
Hemorrhage (SAH) 
Bleeding within the subarachnoid space, between the surface of the 
brain and arachnoid layer. May include blood in ambient, basal, 
interpenduncular cisterns or cisterna magna, or along falx or tentorium 
Intra-ventricular 
Hemorrhage (IVH) 
Blood documented within intra-ventricular space 
Epidural Hematoma 
(EDH) 
Presence of extra-axial collection within epidural space, between skull 
and dura matter 
Penetrating TBI  
(pTBI) 
Typically defined by penetration of the dura matter. May include bone, 
metal, or other foreign bodies present within the parenchyma, skull 
fractures displaced or depressed > 2mm, or “through and through” 
injuries penetrating the dura 
 
1.1.2 Epidemiology 
The incidence of traumatic brain injury and its sequelae documented in the existing literature is 
heavily influenced by many factors, most importantly injury severity and type. In the United 
States, approximately 2.5 million traumatic brain injuries occur annually3. Of these, 
approximately 284,000 (11%) result in hospitalization, and 53,000 (2%) in death3. However, 
these figures are limited by their reliance on national surveillance data and cannot account for 
individuals with TBI that do not seek care, or for those who seek care from a primary care 
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physician only. Therefore, it is likely that these data are an underestimate of the incidence of 
TBI, particularly mild TBI, in the United States.  
Despite this limitation, national surveillance data show trends of increasing overall TBI 
incidence and emergency department visits related to TBI from 2001 to 2010 (Figure 1). The 
observed increase may be influenced by recent public health campaigns to increase awareness of 
mild TBI (mTBI), leading to an increase in health care utilization associated with mTBI.  
 
Figure 1. Rates of TBI Related Emergency Department Visits, Hospitalizations, and Deaths 
- United States, 2001-2010 
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This theory is supported by the relatively constant incidence of TBI hospitalizations 
throughout the same timeframe, suggesting the frequency of moderate and severe TBI requiring 
hospitalization is not increasing and the resulting overall increase is likely attributable to more 
mild injuries. Also within the last decade, rates of TBI-related death have decreased in the 
United States 13.  
Across all injury severities, as classified by the GCS, males have consistently higher rates 
of TBI compared to females 14; 15. There are also significant differences in risk of TBI across the 
lifespan. Individuals ages 0 to 4, 15 to 19, and greater than 65 years old are at a significantly 
increased risk of TBI 14; 16; 17. Of these age groups, individuals greater than 75 years old have the 
highest rates of hospitalization and death 13; 15; 17.  
Differences in TBI rates across race and ethnicity are also documented. Annual TBI rates, 
including emergency department utilization and hospitalizations, are higher for black individuals 
than white and those of other racial backgrounds. However, annual average mortality rates are 
lower for black individuals compared to whites 17.  
1.1.3 Primary and Secondary Injury 
The highly heterogeneous nature of traumatic brain injury makes it difficult to establish 
standards of care across the spectrum of injury. There are currently no therapeutic interventions 
proven to be effective across a broad range of clinical presentations of TBI. Similarly, outcomes 
vary greatly and are difficult to predict based solely on injury severity.  Differences in 
neurobiological factors, such as those involved in secondary injury, likely contribute 
substantially to differences in outcome.  
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Mechanistically, traumatic brain injury can be thought of as two events occurring 
successively. The first event, the primary injury, refers to the moment of impact of external 
forces causing the TBI. The primary injury is a discrete event.  
Unlike the primary injury, the secondary injury is often thought of as a cascade, initiated 
by the primary injury and evolving over time. The secondary injury is not discrete; it is 
composed of multiple pathophysiological processes that may occur simultaneously or 
sequentially and are not consistent across individuals. Different primary injury types (i.e. diffuse 
axonal injury, intra-cerebral hemorrhage, or penetrating injury) may initiate different secondary 
injury cascades 18. However, this too may differ across individuals. It is necessary to understand 
the pathological processes that encompass secondary injuries and their impact on TBI 
complications, especially development of PTS.  
Briefly, the secondary injury cascade has been described as a two-stage process, with 
multiple pathological processes occurring 19. Among the first pathological processes to take 
place are direct tissue damage, abnormalities in cerebral blood flow, and deregulation and 
functional impairment of cerebral metabolism 19. Damage to brain tissue including disruption 
and/or destruction of cerebral blood vessels can result in cerebral ischemia. Multiple studies have 
documented both focal and global episodes of cerebral ischemia following TBI 20-22.  
Adding to the cerebral ischemic state, damage from the primary injury to neuronal, glial, 
and endothelial cells can disrupt the brain’s autoregulatory pathways. Vasoconstriction and 
vasodilation are well-documented examples of autoregulatory pathways that may be impaired, or 
completely decimated, following TBI 23-25. Autoregulatory dysfunction can also cause 
hypotension and hypoperfusion, progressively leading to metabolic dysfunction and inability to 
 8 
meet glucose demands 19; 26; 27. Despite documentation of disrupted pathways, there are no 
consistent findings regarding the timing of impairment or loss of autoregulatory.  
Precise control of cerebral metabolism is vital to maintain proper neurological function 
22. Failure to maintain cerebral metabolism and energy demands leads to mitochondrial 
dysfunction, decreased ATP production, and chemical and ionic imbalances within cells 19; 28. 
Each of these events can cause cell death, contributing to poor outcome following TBI. 
Traumatic brain injury can also induce depolarization of the neuron and excessive release 
of excitatory neurotransmitters, such as glutamate 6; 29. The excitotoxicity pathway is further 
enhanced by impairment of glutamate uptake and glutamate receptors following injury 30. 
Inability to compensate for excessive glutamate release can cause subsequent breakdown of the 
blood brain barrier, further disrupting ionic balance 31; 32. Trying to restore proper 
neurotransmitter and ion levels increases metabolic demands on tissues that may already be 
suffering from metabolic dysfunction due to pathological processes described above 33. Inability 
to break this cycle and restore balance can lead to cell death.  
Oxidative stress, the production and release of reactive oxygen species, often occurs in 
response to excitoxicity following primary TBI 34-36. Oxidative stress can then induce additional 
pathological processes leading to immediate cell death 36, as well as activating inflammatory 
processes 34.  
Inflammatory processes can occur immediately in response to primary injury and tissue 
damage, or in response to secondary injury cascades. The inflammatory process following TBI is 
extremely complex and can persist well into the chronic phase 37. As part of the inflammatory 
response, cytokines are released, activating subsequent proteins such as chemokines and 
adhesion molecules that are responsible for activating glia, importantly microglia, and other 
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immune cells 38. Activated microglia and immune cells adhere to damaged and potentially non-
damaged cells surrounding the damaged tissue, ultimately leading to cell destruction 19; 39. This 
process can spread across tissues, continue for sustained periods of time post-injury, and activate 
astrocytes to produce glial scarring in the effected regions 40. 
 Many of the same pathological processes taking place in response to TBI can be found 
during epileptogenesis. Thus, TBI primes the brain for ictogenic activity, a condition that can 
persist decades following the primary injury. 
1.2 POST TRAUMATIC SEIZURES 
1.2.1 Definitions and Classification 
Simplistically, post-traumatic seizures (PTS) refers to an incident seizure following head trauma. 
The definitions and classification systems for PTS vary throughout the literature and have 
changed across time. These differences make it difficult to compare findings across multiple 
studies and to aggregate data for use in meta-analyses.  
Post-traumatic seizures are classified based on time of seizure: immediate (<24 hours), 
early (1 to 7 days), and late (>7 days) post-injury41 (Table 3). Immediate and early seizures are 
considered provoked and decrease seizure threshold only temporarily after TBI 42. Recently, the 
term acute symptomatic has been used to describe provoked seizures43; 44.  Cut-points for PTS 
classification are based on hypothesized differences in causal pathology and epileptogenic 
potential 18; 31; 45; 46.  
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Late PTS and post-traumatic epilepsy (PTE) are often used interchangeably 47; 48. 
However, some studies make clear distinctions between PTS, late PTS, and PTE. The distinction 
typically lies in the intricacies involved with the definition of epilepsy, which has changed over 
time, and in the timeframe post-injury in which the first seizure occurs. Some studies use time of 
first seizure to delineate PTS from PTE. In these instances, PTS is used to refer to seizures 
occurring early, up to seven days post-injury; PTE is then used to refer to seizures that occur 
after seven days 49; 50. Other previous research has previously differentiated PTS from PTE based 
on the number of seizures that occurred. Earlier definitions of epilepsy required the occurrence 
of two or more unprovoked seizures >24 hours apart. Using this information, many researchers 
defined PTE as more than one seizure occurring after 7 days post-injury; some studies then used 
late PTS to describe a single seizure occurring after 7 days post-injury 18; 51-54.  
Recently, the International League Against Epilepsy (ILEA) made the recommendation 
to revise and operationalize the definition of epilepsy. The ILEA concluded that requiring two 
unprovoked seizures to diagnose epilepsy was no longer adequate to accurately capture the 
clinical variability across epilepsy disorders 55. Therefore, the recommendation was made to 
revise the definition of epilepsy and include conditions where an individual has a single 
unprovoked seizure and their risk of a recurrent seizure is similar to, or greater than, the risk of 
seizure recurrence after two unprovoked seizures occurring ≥24hrs apart (≥60%)42. These 
recommendations were adopted as the official position by the ILAE in December 2013, thus 
changing the definition of epilepsy 42. 
 
 
 
 11 
Table 3. Overview of Current and Past Definitions for Classification of Seizures Occurring 
 after Traumatic Brain Injury 
 Classification Definition 
Current Definition Immediate 
PTS1 
Seizure occurring <24 hours post-injury 
 Early PTS1 Seizure occurring 1 – 7 days post-injury 
 Late PTS2 Seizure occurring >7 days post-injury 
 PTE Seizure occurring >7 days post-injury; 
synonymous with late PTS  
(not used in current work) 
Past Definitions  PTS Single seizure occurring post-injury 
 PTE Two or more seizures occurring >7 days 
post-injury 
 PTS Seizures occurring ≤7 days post-injury 
 PTE Seizure occurring >7 days post-injury 
 Late PTS Single seizure occurring >7 days post-
injury 
1Also referred to as acute symptomatic 
2Individuals with immediate and early PTS remain at risk of developing late PTS 
 
Previous research on seizure recurrence following a single, unprovoked seizure >7d post-
TBI documents risk of seizure recurrence is high enough to consider late PTS as an epileptic 
condition42; 56. Haltiner and colleagues determined, of individuals with a single late post-
traumatic seizure, 86% will have a second seizure within two years 56. Following with the most 
current clinical definitions of epilepsy, PTE would be defined as one or more seizures occurring 
after 7 days post-injury. Therefore, late PTS and PTE are equivalent. For the purposes of this 
work, PTS including immediate, early, or late classification will be used to refer to post-
traumatic seizure activity. Importantly, individuals with immediate or early PTS who have a 
subsequent late seizure can be classified as having late PTS (i.e. PTE).  
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1.2.2 Mechanisms 
Post-traumatic seizures may arise from multiple pathological mechanisms initiated by traumatic 
brain injury. While it is hypothesized that acute symptomatic and late seizures result from 
different pathological mechanisms 18, multiple epileptogenic processes can occur within one 
individual.  
Epileptogenesis refers to the process through which a healthy, normally functioning brain 
transforms into a brain characterized by a predisposition toward seizure activity 31. Inherent to 
epileptogenesis is a latent time period before the initial epileptic seizure occurs during which 
cellular and molecular changes are taking place. Following TBI, these cellular and molecular 
changes can occur as a part of secondary injury cascades. Because the primary injury is an acute 
event, TBI allows the prospective investigation of epileptogenic processes, which is not feasible 
with epilepsies of non-traumatic etiology.  
Excitotoxicity is one such mechanism that may predispose the brain to epileptic seizure 
activity and can occur as a result of TBI via secondary injury cascades as discussed above 
(Section 1.1.3). Immediately following injury, there can be a substantially large release of 
excitatory neurotransmitters, particularly glutamate57; 58; this release may cause excitotoxicity, 
triggering seizures and other excitotoxic injury 29; 31; 59. These immediate seizures, in direct 
response to release of excitatory neurotransmitters would be considered provoked, and therefore 
would not meet the definition of epileptic seizure activity 31; 55. However, excitotoxicity can lead 
to neuronal and astrocytic swelling, mitochondrial damage, cell death, and immediate/early 
PTS60. Seizures can cause over-activation of excitatory amino acid receptors, inducing calcium 
dependent production of nitric oxide and reactive oxygen species and free radical damage to 
DNA and cellular membranes 18. These observations suggest decreased glutamate clearance, and 
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low-level excitoxicity, is an ongoing mechanism of TBI pathology and contributor to 
epileptogenesis. Antecedent immediate/early seizure activity may, along with altered glutamate 
transporter expression, perpetuate excitoxicity and cell death and contribute to epileptogenesis 6; 
61. 
Glutamate levels must be carefully regulated via release and reuptake to prevent 
excitotoxic injury. There are five glutamate transporters with distinct cellular, synaptic, and 
regional distributions within the human brain, each encoded by a different gene 62. It is possible 
that dysfunction of glutamate transporters, from injury or genetic predisposition toward a 
reduced function, could potentially increase seizure susceptibility through excitoxicity, decreased 
antioxidant reserves, or decreased inhibitory neurotransmission.  
Additional epileptogenic processes related to inflammation and glial activation have been 
identified. As previously described (Section 1.1.3), the inflammatory response can begin 
immediately following TBI and persist chronically37. Activated glia adhere to damaged cells and 
initiate a feedback loop with immune cells and pro-inflammatory factors38. This feedback loop 
can cause neuronal injury, promote glial scar formation, and decrease glutamate re-uptake, all of 
which contribute to epileptogenesis 40; 62. The occurrence of epileptic seizure activity can also 
maintain this cycle of glutamate release, inflammation, neuronal injury, and glial activation 62.  
Ultimately, there are numerous mechanisms that can contribute to epileptogenesis, many 
of which are initiated by secondary injury cascades. Increasing research regarding biomarkers for 
PTS may help to delineate pathological processes taking place within sub-groups of individuals. 
If possible, knowledge of specific epileptogenic processes occurring within individuals could 
also provide new targets for prevention of PTS, particularly late PTS. 
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1.2.3 Epidemiology 
The incidence of PTS varies widely within the literature and is dependent upon many factors 
including study design, population characteristics, and how PTS is defined. To date, few large 
epidemiological studies of PTS have been conducted. The exact percentage of individuals with 
TBI who will develop PTS, including late PTS (PTE), remains unknown 54.  
The incidence of acute symptomatic seizures has not been well described. Of studies that 
document early PTS, most do not differentiate immediate from early seizures, nor do they 
specify if immediate and early seizures are considered concurrently. In a population based study 
from Rochester County Minnesota, Annegers and colleagues reported 2.1% of individuals with 
TBI (all severities) developed early PTS63, and of these, approximately 76% of individuals 
seized within the first 24 hours post-injury. This study included all ages and TBI severity ranges, 
but when individuals with severe TBI only were considered, the documented incidence of early 
PTS increased to 10.3%63. Smaller studies that do not differentiate immediate from early seizures 
document early PTS incidence to range from approximately 2% to 17% 12; 45; 47; 64; 65. Although, 
incidence rates as high as 25% 66 and as low as 0.9%67 have been reported in a cohort of brain 
injury rehabilitation patients in Finland and a cohort of hospitalized Chinese patients, 
respectively. Within a military cohort, incidence of early PTS falls within the reported range 
(5%) 68. The wide range of early PTS incidence may be due to differences in seizure 
classification and ascertainment methods (i.e. continuous EEG monitoring) or population 
characteristics (i.e. greater proportion of children, pTBI).  
Using the same population from Rochester County Minnesota, Annegers and colleagues 
conducted one of the first and largest population-based studies of late PTS, investigating 
individuals injured between 1935 and 1989. They documented an overall standardized incidence 
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ratio (SIR) of 3.1 for late PTS over the course of full follow-up compared to a demographically 
similar, non-injured population 12. Among those with severe TBI, the five-year cumulative 
probability of late PTS was 10.0%, and increased to 16.7% at 30 years post-injury12. Importantly, 
Annegers and colleagues determined that individuals with severe TBI remained at a significantly 
greater risk of unprovoked seizure throughout the entire study duration compared to expected 
epilepsy rates in the general population. However, this study population was racially and 
socioeconomically homogeneous and results may not generalize to a more diverse population.  
A second, more recent, population-based study in the United States examining a more 
representative sample concluded the incidence of late PTS following TBI of all severities, 
presenting to a participating emergency department, was 2.2 per 100 persons in the first year 
post-injury 69. Incidence increased to 4.1 and 3.1 cases per 100 persons in year two and year 
three, respectively 69. Among individuals with severe TBI, the cumulative incidence of late PTS 
was 13.6 per 100 persons over the first three years post-injury69.  
In a study of individuals with moderate to severe TBI admitted to hospital and requiring 
inpatient rehabilitation, the cumulative probability of late PTS was 13.2% at two years post-
injury 47. Of individuals with late PTS, 80.3% developed late PTS in the first year, and 92.4% of 
cases occurred within the first 18 months following injury 47. Additional smaller studies, in 
primarily adult populations, have reported the prevalence of late PTS to range from 
approximately 5% to 19%66; 67; 70; 71. 
Reported prevalence of late PTS is even higher in military populations, surpassing 53%72; 
73. Compared to studies in primarily civilian populations, military populations have greater 
incidence and prevalence of late PTS. In the longest follow-up study of TBI in a United States 
military cohort, 23% of individuals had new onset seizures in the first year post-injury. 
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Prevalence of late PTS increased to 29% in year two and 53% in year 15; at 35 years post-injury, 
prevalence was estimated at 43.7%68; 72; 73. Eleven (5.5% of study cohort) of the individuals 
followed up to 35 years post-injury reported new onset seizures between the 15 and 35 year 
follow-up interviews 72.  
In an independent cohort of Service Members and Veterans from the Korean War, 7.1% 
of individuals developed PTS in the first week post-injury and 22.7% developed late PTS 45. 
However, this is likely an underestimate of late PTS since it is unclear if individuals with early 
PTS developed seizures after one week post-injury, qualifying them for late PTS (i.e. PTE). The 
majority of late PTS cases (54.2%) within the study cohort developed within one year post-injury 
and 18.1% of cases developed during the second year 45. However, new onset cases continued to 
be ascertained out to 11 years post-injury. 
One very important limitation of the majority of late PTS studies thus far is inherent to all 
epilepsy research: misclassification bias. Seizure activity can present in many different ways. 
Any physiological brain function can manifest during a seizure and it may not be evident to the 
individual that what they are experiencing is in fact, seizure activity. Similarly, not all seizures 
are clinically evident. Subclinical seizure incidence is reported to be higher than incidence of 
clinically recognized seizures and has been reported to be even higher for individuals with 
penetrating brain injury 74. In one study of moderate and severe TBI utilizing continuous EEG 
(cEEG) monitoring up to 14 days post-injury, 22% of individuals were found to have early PTS; 
of individuals with early PTS, 57% of seizures were non-convulsive and only detected as a result 
of continuous monitoring 75; 76. Therefore, incidence rates of immediate and early PTS reported 
in the literature, which are largely based on medical record and billing review, are likely 
underestimates of PTS. For studies of PTS following moderate to severe TBI, where individuals 
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are in a hospital setting and cEEG monitoring is possible, rates may be less biased. But, the risk 
for bias remains, especially if cEEG monitoring is only used on subsets of individuals for clinical 
care, such as those with suspected seizure activity.  
1.2.4 Risk Factors of PTS 
1.2.4.1 PTS at all Time Points 
Few risk factors have been identified for PTS across all time-points (immediate, early, and late). 
Injury severity is the most commonly examined risk factor for PTS. Various algorithms have 
been used to define injury severity (see Table 1, Section 1.1.1). Within the literature, there is 
general agreement that greater severity is associated with increased risk of PTS in all timeframes 
12; 50; 63; 66; 67; 69-71; 77-79. 
Where there are slight differences in results regarding severity as a risk factor, the 
method used to categorize severity may be responsible. Englander and colleagues found the 
highest cumulative probability of late PTS among individuals with moderate TBI, classified by 
GCS (GCS 9-12), over the first two years post-injury 47. However, this finding highlights the 
construct of survival bias, particularly for late PTS. Individuals with severe TBI are more likely 
to expire within the first week post-injury, excluding them from being at risk for development of 
late PTS.  
Further complicating the effect of injury severity on PTS, specifically immediate and 
early PTS, when continuous EEG monitoring is used to ascertain cases, there is no significant 
difference in injury severity, as measured by the GCS, between individuals who seize and those 
who do not 76. As such, increasing injury severity may correlate with increasing risk of late PTS, 
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limited to clinically apparent seizures. Using consistent metrics to classify injury and to ascertain 
PTS status would increase comparability of findings across studies.  
Injury characteristics have been extensively studied as risk factors for PTS. As CT 
imaging became common practice following head trauma, specific pathology types were also 
examined. Presence of intra-cerebral blood, including intracerebral hemorrhage and subdural 
hematoma, has been identified as a risk factor for early and late PTS, increasing risk up to 30% 
12; 47; 48; 50; 63; 71; 78; 80; 81. While pTBI is often associated with late PTS, depressed skull fracture has 
been specifically documented as a risk factor for both early and late PTS 12; 50; 63; 66; 78; 82.   
In addition to injury severity, age at injury is consistently cited as a risk factor for PTS. 
Children are at an increased risk of PTS at all time-points post-injury, but are particularly prone 
to immediate and early seizures 12; 63; 66; 77; 83. The effect of age within adult populations is less 
clear. The Rochester Epidemiology Project found age greater than or equal to 65 was associated 
with a late PTS rate ratio of 2.5, which remained significant even after correction for other risk 
factors including early PTS and depressed skull fracture 12. Asikainen et al concluded increasing 
age among adults is correlated with increasing risk of late PTS 66. Yet, other studies found no 
association between age and risk of late PTS 69. Additional research is needed to more 
thoroughly investigate the effect of age on late PTS among adults.  
1.2.4.2 Early PTS 
Characteristics of individuals who develop immediate and early PTS are more highly variable. In 
addition to risk factors for PTS during all timeframes discussed above, few risk factors are 
specific to immediate and/or early PTS. This is likely attributable to the fact that immediate and 
early are considered acute symptomatic seizures, direct responses to the head trauma. Therefore, 
research has not extensively examined risk factors for early PTS outside of injury severity. As 
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more research is conducted, novel risk factors specific to immediate and/or early seizures may be 
identified.  
1.2.4.3 Late PTS 
Penetrating TBI is often defined by dura penetration and may include the presence of bone 
and/or foreign fragments (e.g. shrapnel). In both civilian and military cohorts, pTBI is one of the 
most prominent risk factors for late PTS 46; 47; 66; 68; 72; 73; 78; 84; 85. Salazar and Grafman reviewed 
pTBI in both military and civilian cohorts and documented approximately 34 to 63% of 
individuals with pTBI develop late PTS 86. Similarly, the highest probability of developing PTE 
in a civilian population, 62.5% in two years post-injury, was associated with bone or metal 
fragments and a relative risk of 3.94 compared to those with no dura penetration47. Penetrating 
TBI is much more common in military cohorts compared to civilian cohorts 56; 72 and may 
explain the reported differences in rates of late PTS.  
Among individuals with late PTS, Weiss and Caveness found no statistically significant 
differences in seizure frequency for those with penetrating compared to non-penetrating TBI 45. 
Interestingly, a penetrating wound greater than 3 cm deep was highly associated with increased 
seizure frequency 45, suggesting deep brain penetration may initiate different pathophysiological 
pathways leading to increased seizure.  
As CT technology became increasingly available and used as part of the standard of care 
to diagnose TBI, abnormal neuroradiological findings were identified as risk factors for late PTS. 
Englander and colleagues found cisternal compression and midline shift, often associated with 
presence of intracranial bleeding and elevated intracranial pressure (ICP), were significantly 
associated with late PTS in a cohort of individuals hospitalized for moderate to severe TBI 47. In 
addition to intracerebral blood collection (i.e. SDH, ICH), multiple studies have documented 
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contusion as a significant risk factor for late PTS 12; 47; 64; 67; 78; 87; 88. In a large population-based 
study, brain contusion and subdural hematoma remained significantly associated with late PTS 
after adjusting for additional risk factors including linear skull fracture, depressed skull fracture, 
and early seizure [rate ratios (95% CI); SDH: 6.3 (2.2-18.0), contusion: 5.0 (2.5-10.0)] 12. Risk of 
late PTS has also been shown to vary based on specific location of contusion (e.g. temporal) 47; 
70, likely related to certain brain regions/structures being more susceptible to seizure activity 
independent of TBI. 
While few previous studies have specifically examined risk factors for early PTS, many 
studies document seizures occurring in the first week post-injury as a significant risk factor for 
late PTS. In univariate models, early seizures were shown to approximately double the 
probability of late PTS 47; 78. Angeleri et al determined the relative risk of late PTS was 
approximately 8.6 (95%CI: 2.9-25.6) for individuals with at least one early seizure compared to 
those with no early seizure activity 70. Early seizures were also found to significantly increase 
risk for late PTS in multivariable models 66; 69. Contrary to these findings, early seizures were not 
determined to be significantly associated with late PTS in the Rochester Epidemiology Project 
cohort after controlling for other known risk factors 12. Despite the majority of evidence 
indicating early seizures increase risk of late PTS, it remains unknown if immediate and early 
seizures have different effects on risk of lat PTS.    
With advances in medicine and neuro-critical care, neurosurgical procedures have 
become common interventions following severe TBI. Neurosurgical procedures may include 
ventriculostomy, craniotomy, and craniectomy. Previous research indicates that neurosurgical 
interventions increase risk of late PTS 47; 78. However, craniotomy and craniectomy are 
implicated as risk factors for seizure, even when used to address non-traumatic CNS pathologies 
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89. Thus, its possible post-operative seizures within a certain timeframe may be considered acute 
symptomatic and not late PTS (i.e. PTE). Further research is needed to more comprehensively 
describe temporal trends of seizure activity post-surgery.   
In addition to injury related characteristics, recent studies have investigated the effect of 
pre-morbid personal and medical history on late PTS. In a population-based sample of 
individuals hospitalized for TBI, pre-morbid history of depression [adjusted risk ratio (95% CI): 
1.85 (1.16-2.94)] was significantly associated with increased risk for late PTS in multivariable 
analysis 69. In earlier studies, pre-morbid chronic alcoholism was also documented to be 
associated with development of late PTS 71; 80. Although, seizures may also be caused by alcohol 
withdrawal and the duration of time between alcohol cessation and seizure development should 
be carefully inspected to ensure acute symptomatic seizures secondary to withdrawal44 are not 
indicated as late PTS. Moreover, there is a bidirectional relationship between alcohol use/misuse 
and epilepsy 88; 90 and further research is needed to more thoroughly examine the effect of 
alcoholism on late PTS.    
1.2.4.4 Genetic Variance  
Few studies have examined genetic variance and possible associations with PTS. Of those that 
have, a candidate gene approach, as opposed to a genome wide approach, has been adopted and 
relatively few genes have been examined. Potential candidate genes have been identified from 
neurobiological pathways associated with secondary injury cascades as well as non-traumatic 
epileptogenic mechanisms. Candidate gene studies are preferred within TBI research due to the 
large sample sizes required to power genome wide association studies (GWAS). No current 
studies of TBI that collect biological samples are sufficiently large enough to support the use of a 
GWAS approach.  
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Apolipoprotein E (apoE) ε4 has been previously associated with poor outcome following 
TBI and is associated with other neurodegenerative diseases such as Alzheimer’s Disease 91-93. 
Therefore, apoE ε4 has been investigated as a potential risk factor for late PTS. Initial findings in 
a small cohort (n=106) of moderate to severe TBI indicate individuals with the ε4 allele are at an 
increased risk for late PTS (RR: 2.41, 95% CI: 1.15-5.07) compared to individuals without the ε4 
allele 94. Unfortunately, this result was not replicated in a second civilian cohort of moderate to 
severe TBI or in a military cohort 72; 95. 
A single study has identified a significant association between a known functional variant 
in the methylenetetrahydrofolate reductase (MTHFR) gene, C677T, and late PTS. The MTHFR 
gene is essential for metabolism of methionine and has previously been found to be associated 
with neurodegenerative diseases and migraine 96-98. In a recent case-control study of Service 
Members, odds of late PTS were significantly greater for individuals with the TT genotype (OR: 
1.92, 95% CI: 1.01-3.64) compared to CC individuals 99. The association was made stronger 
when the classification of late PTS was revised to include only those with two or more seizures, 
and remained significant in multivariable analysis (AOR: 2.55, 95% CI: 1.12-5.80) 99. 
Interleukin 1-beta (IL-1β) is a pro-inflammatory cytokine produced by activated glia in 
the CNS. The inflammatory response associated with secondary injury cascades following TBI 
can increase IL-1β expression, and increased IL-1β levels can be observed chronically post-
injury 100. IL-1β may also contribute to excitotoxicity and epileptogenic mechanisms 101. To date, 
one study has examined the effect of genetic variation within the gene encoding IL-1β on risk of 
PTS. Investigation revealed SNP rs1143634 was associated with differences in IL-1β 
cerebrospinal fluid (CSF)/serum ratios 102. Additionally, heterozygous individuals had 
significantly greater risk of late PTS (hazard ratio: 2.85, 95% CI: 1.37-5.90) after adjusting for 
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injury severity, SDH, and depressed skull fracture; the relative effect of rs1143634 genotype was 
greatest of all variables in the model 102. 
In addition to single candidate gene studies, previous research has examined multiple 
genes within pathways related to epileptogenic mechanisms. Various genes related to the 
adenosine regulatory cycle were examined in a single study of late PTS within a cohort of 
individuals with moderate to severe TBI. After investigating genes encoding adenosine kinase 
(ADK), ecto-5’-nucleotidase (NT5E), and equilibrative nucleoside transporter type-1 (ENT-1), 
Diamond and colleagues found rs11001109 (ADK) minor allele homozygous and rs9444348 
(NT5E) heterozygous individuals were at increased risk of late PTS 102. These findings remained 
significant after controlling for injury severity and SDH. An additional study in a similar sample 
examined the potential effect of adenosine A1 receptor (A1AR) genetic variation on PTS. SNP 
rs3766553 minor allele homozygous individuals were at greatest risk of early PTS 103. 
Conversely, rs3766553 major allele homozygous individuals had significantly greater risk of late 
PTS. SNP rs10920573 heterozygosity was also associated with increased risk of late PTS 103.  
Variation in glutamatergic and gamma-amino butyric acid (GABA) related pathways, 
important for maintenance of the excitatory/inhibitory balance, has also been investigated. Two 
studies specifically looked at genetic variation within glutamic acid decarboxylase (GAD) genes 
and possible associations with PTS. In a civilian cohort of moderate to severe TBI, tagging SNP 
rs3828275 (GAD1) was significantly associated with early PTS; two additional SNPs, tagging 
SNP rs769391 and functional SNP rs3791878, were associated with risk of PTS from one week 
to 6 months post-injury 104. A second study of GAD genetic variation in a military cohort also 
identified an additional tagging SNP significantly associated with late PTS assessed at 15 years 
post-injury 72. In the same cohort, SNP rs11074504 within GRIN, a gene encoding a glutamate 
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receptor subunit of the N-methyl-D-aspartate (NMDA) receptor, was significantly associated 
with late PTS 72. However, no associations identified within the military cohort remained 
significant after correcting for multiple comparisons.  
Although each of these initial candidate gene studies must be further explored to 
determine if results can be replicated in additional populations, these findings provide 
preliminary support for the role of genetic variation in the development of PTS. It is likely that, 
in the future, genetic information may facilitate a more personalized medicine approach to PTS 
risk assessment, prophylaxis, and treatment.  
1.3 SUMMARY 
Traumatic brain injury and post-traumatic seizures are a significant public health problem. 
Chronic complications of TBI incur tremendous costs in healthcare utilization, time from family 
and caregivers, and increased morbidity and mortality. PTS is a well-recognized complication of 
TBI that contributes greatly to the cost associated with chronic complications of TBI. As 
incidence of TBI increases and death rates decrease, more individuals will be living with the 
chronic complications of TBI, including PTS.  
There has been a large effort within previous research to examine the epidemiology of 
PTS, particularly late PTS, to identify risk factors and propose interventions. Despite these 
efforts, variability in who will develop PTS remains high. Few studies have examined additional 
characteristics such as premorbid conditions, acute care complications, or genetic variation that 
may increase the risk of PTS. Additionally, while prophylaxis is effective for suppressing early 
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seizures, there remains no effective pharmacotherapy or targeted intervention to prevent late 
PTS. 
 Therefore, it is vitally important to continue examining PTS to determine if and how the 
epidemiology is changing in large, heterogeneous populations, and to identify additional risk 
factors that may help predict PTS and time of onset. Identifying genetic variation associated with 
PTS may help provide insight as to why some individuals develop PTS and others with similar 
injuries do not. Together, these additional data may improve PTS prognostication, expound upon 
epileptogenic mechanisms following TBI, and identify new targets for intervention.  
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2.0  SPECIFIC AIMS 
2.1 CHARACTERIZATION OF PTS 
Multiple studies examining the epidemiology of PTS have been conducted. However, there are 
limitations regarding generalizability of previous findings. Furthermore, immediate and early 
PTS are often excluded from large epidemiological studies that focus primarily on late PTS (i.e. 
PTE). In order to fully understand the potential public health significance of PTS, more detailed 
information on the epidemiology of all PTS classifications in a large, representative population is 
required.  
2.1.1 Specific Aim 1 
Characterize the frequency of post-traumatic seizure at various time points post-injury, within a 
cohort of individuals with moderate to severe TBI 
 We expect incidence and prevalence of PTS will be similar to previous studies using 
similar populations. Stratified analyses may confirm established risk factors for late PTS and 
provide insight into novel risk factors for immediate and early PTS. 
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2.2 IDENTIFICATION OF PREDICTORS AND RISK FACTORS FOR PTS 
Although many potential risk factors for PTS have been identified, there remains a high degree 
of variability in who will develop PTS. Previous research has attempted to develop prognostic 
models to aid clinicians in determining an individual’s PTS risk. These attempts were made 
decades ago, were never adopted for clinical use, and are not representative of current trends in 
TBI severity, diagnosis, or treatment. To more definitively assess the potential usefulness of 
prognostic models for PTS in research and clinical care, revised models must be developed.  
 Similarly, technology to assess potential risk factors related to personal biology is now 
more accessible in research and clinical practice. Novel genetic risk factors for PTS have 
recently been identified. Further research regarding the effect of genetic variation on PTS risk is 
essential to identify potential risk factors and neurobiological mechanisms that may represents 
points of intervention for PTS prophylaxis and treatment.  
2.2.1 Specific Aim 2 
Develop prognostic models to predict PTS during acute care hospitalization, at Year 1, and Year 
2 following traumatic brain injury.  
Hypothesis 2.2.1. A: Personal, medical, and injury characteristics will be identified as 
significant predictors of PTS 
Hypothesis 2.2.1. B: Significant predictors of PTS will vary based on time PTS is 
assessed post-injury 
Hypothesis 2.2.1. C: Prognostic models will be internally validated  
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2.2.2 Specific Aim 3 
Examine the effect of genetic variation within neuronal glutamate transporter genes, SLC1A1 
and SLC1A6, on epileptogenesis following severe traumatic brain injury.  
Hypothesis 2.2.2. A: Genetic variation in the neuronal glutamate transporter genes, 
SLC1A1 and SLC1A6, will be significantly associated with epileptogenesis and 
PTS  
Hypothesis 2.2.2. B: Different genetic variants will be associated with epileptogenesis 
during different subcomponents of the three-year post-injury timeframe 
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3.0  BACKGROUND 
3.1 STUDY POPULATIONS 
3.1.1 Traumatic Brain Injury Model Systems 
The Traumatic Brain Injury Model Systems (TBIMS) study is an ongoing multi-center, 
prospective, observational cohort study. Established in 1987, there are 16 currently funded 
centers including the University of Pittsburgh and four previously funded centers that continue to 
collect follow-up information 105. The main objective of the TBIMS program is to study recovery 
and outcomes after moderate to severe TBI. Individuals participating in the TBIMS study have 
the potential to be followed from inpatient rehabilitation for TBI throughout the duration of their 
lifespan. Currently, the longest follow-up time-point is 25 years post-injury. All data collected 
through the TBIMS program is deposited to the TBIMS National Data and Statistical Center, 
where it is formatted into the TBIMS National Database (NDB), the central resource for all 
TBIMS research.  
TBIMS Centers are established and funded through center-specific grants, typically 
awarded for five-year periods 106. To be eligible, a Center must provide a “multidisciplinary 
system of rehabilitation care specifically designed to meet the needs of individuals with TBI” 107. 
To fulfill this requirement, a participating Center must include emergency medical services 
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(most commonly at least one Level-1 trauma center), acute care including neurosurgical 
capabilities, comprehensive inpatient rehabilitation, and long-term interdisciplinary follow-up 
and rehabilitation services. The number of acute care hospitals within a single TBIMS Center 
may vary. The TBIMS Center must be able to access emergency and acute care records, 
however, it is not required that acute medical and rehabilitation facilities be within the same 
hospital system. TBIMS Centers must include at least one Center specific study, participate in at 
least one multicenter study, and collect and submit longitudinal data to the TBIMS-NDB.  
The TBIMS program specifies inclusion criteria for all individuals enrolled at any 
participating Center. Throughout its history, the TBIMS program has revised participant 
inclusion criteria. The current inclusion criteria are defined below. Firstly, an individual must 
meet the TBIMS case definition of TBI.  
Damage to brain tissue caused by an external mechanical force as 
evidenced by medically documented loss of consciousness or post-
traumatic amnesia (PTA) due to brain trauma or by objective neurological 
findings that can be reasonably attributed to TBI on physical examination 
or mental status examination 108 
All participants must have a moderate to severe TBI defined by at least one of the 
following classifications: post-traumatic amnesia >24 hours, trauma related neuroimaging 
abnormality, loss of consciousness >30 minutes, or emergency department GCS<13 (not 
influenced by intubation, sedation, or intoxication). Additionally, all participants must be 16 
years or older, present to a TBIMS Center affiliated emergency department within 72 hours of 
injury (previously 24 hours), receive acute and comprehensive inpatient rehabilitation within the 
Center’s designated facilities, and provide written informed consent.  
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Data from emergency and acute care, referred to as Form 1, is collected retrospectively. 
Data from inpatient rehabilitation and at all follow-up interviews, referred to as Form 2, are 
collected prospectively. Follow-up interviews are currently conducted at 1, 2, 5, and every five 
years thereafter, post-injury. Over the course of the TBIMS program, follow-up intervals and 
variables collected have been revised. At the time of analysis, there were 285 variables collected 
via Form 1 and 243 variables collected at each follow-up using Form 2. Data in the TBIMS-
NDB collected through the end of the first fiscal quarter of 2015 (October 2014) were used for 
the current analyses. This included 13,241 cases with Form 1 data and 41,733 follow-up 
interviews.  
The TBIMS-NDB has previously been extensively studied to determine its 
generalizability to the United States population 105; 109; 110. TBIMS investigators have recently 
compared the TBIMS study population to the Uniform Data System for Medical Rehabilitation 
(UDS) and eRehabData. The UDS and eRehabData were combined to form a national dataset 
consisting of individuals 16 years or older with a primary diagnosis of TBI who received 
inpatient rehabilitation services. Demographic, socioeconomic, and rehabilitation outcomes were 
then compared between the combined dataset and the TBIMS-NDB. These studies confirm the 
TBIMS-NDB is largely representative of individuals receiving inpatient rehabilitation services 
for TBI in the United States 105; 109; 110. However, the TBIMS-NDB was determined to include a 
larger proportion of individuals under age 65 and a greater proportion of individuals employed 
prior to injury 110. Additionally, individuals in the TBIMS-NDB had a significantly shorter 
length of stay in inpatient rehabilitation compared to the US TBI rehabilitation population 110. To 
address these differences, methods have been developed to weight the TBIMS-NDB to represent 
the general US population of individuals receiving inpatient rehabilitation  
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Additional limitations of the TBIMS study include those inherent to other multi-site 
longitudinal studies such as loss to follow-up. Total loss to follow-up is approximately 24% with 
varying estimates at each time point. Individuals lost to follow-up may differ across time-points. 
Similarly, Centers may lose funding during certain cycles resulting in loss to follow-up of the 
individual Center’s cohort during that funding cycle. Attrition due to loss of Center funding is 
approximately 4% overall and does not surpass 6% for any one follow-up time-point (Table 4).    
Table 4. Sample Size and Attrition Rates of the TBIMS-NDB as of March 31, 2015 
Time Point Number Included % Attrition % Additional Attrition* 
Form 1 13,667 NA NA 
Form 2 45,499 19 4 
Year 1 12,973 15 3 
Year 2 11,518 16 5 
Year 5 8,952 18 5 
Year 10 4,684 19 6 
Year 15 1,588 14 6 
Year 20 449 14 0 
*additional attrition due to loss of Center funding
3.1.2 University of Pittsburgh Local Project 
Multiple smaller studies of moderate to severe TBI have been, or are currently being conducted 
at the University of Pittsburgh. Under the oversight of Dr. Amy Wagner, an overarching study 
protocol has been developed to collect biological samples in order to analyze various potential 
biomarkers and their associations with TBI outcomes. The study objectives include investigating 
the association between genetic variation and development of PTS after moderate to severe TBI.  
For the current analyses, individuals 18 years of age or older with a severe TBI 
(determined by a GCS score ≤8 on admission to the UPMC Level 1 trauma center) were 
included. Individuals were excluded if they had less than three years of follow-up from the time 
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of their index TBI. Information on outcomes of interest, including seizure activity, was extracted 
from the UPMC electronic medical record using a standardized protocol.  
3.2 PROGNOSTIC MODELING 
Prognostic models are statistical tools that estimate an individual’s risk for developing an 
outcome of interest based on specific characteristics 111. Prognostication is common in medical 
research and practice; prognostic models have previously been developed for use in multiple 
fields such as oncology, cardiology, and neonatology. Within the field of research surrounding 
TBI, prognostic models have been investigated to predict multiple outcomes such as survival, 
disability, and global outcome 112-115. Importantly, especially because the etiology of secondary 
injury mechanisms in TBI and epileptogenesis are extremely heterogeneous, the aim of 
prognostic modeling is not to explain causality of the outcome 111. Prognostic models may 
include predictors that are not themselves causal, but may be measuring latent variables that have 
not, or cannot, be measured.   
The development of reliable, validated prognostic models is essential for models to be 
clinically useful. The gold standard for validating a prognostic model is through the use of a 
second, independent study cohort (i.e. external validation). However, this may be prohibitive in 
some specialties and recent advances in statistical methods for validation have been made.  
Resampling methods are reported to be extremely proficient as a means of internally 
validating a statistical model 116; 117. As computing capabilities increase, resampling methods 
such as bootstrapping, are more readily available and widely used. Bootstrapping is a procedure 
that involves selecting a sample, with replacement, from an original dataset. Researchers can 
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indicate the number of samples selected and specify parameters of interest (e.g. sample must 
always include a designated ratio of males to females). A prognostic model of interest can be 
identified a priori and tested for fit using each bootstrapped sample 118. Information from 
bootstrapped samples is aggregated to determine overall fit statistics such as discrimination and 
calibration of the pre-specified model 116; 117; 119.   
 Currently, automated programs are available using statistical software, such as R, to 
streamline these processes 118; 120. In addition, computer modeling can be used to develop 
reduced models (i.e. model development using stepwise elimination) while decreasing 
subjectivity and the potential for investigator bias.  Each bootstrap sample may therefore 
indentify a different set of prognostic variables. These data are simultaneously aggregated to 
determine the best-fit model allowing for user specification (i.e. AIC or alpha thresholds for 
variable inclusion/exclusion) 118. After automated development, the model can be tested for fit 
using the original sample set and the bootstrapped samples, allowing for computation of fit 
statistics as above 116; 119.  
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4.1 ABSTRACT 
Objective: Determine the incidence of post-traumatic seizures (PTS) following traumatic brain 
injury (TBI) among individuals with moderate-to-severe TBI requiring rehabilitation and 
surviving at least 5 years. 
Methods: Using the prospective TBI Model Systems National Database, we calculated the 
incidence of PTS during acute hospitalization, and at Years-1, 2, and 5 post-injury in a 
continuously followed cohort enrolled between 1989 and 2000 (n=795). Incidence rates were 
stratified by risk factors of interest, and relative risk (RR) was calculated. The RR of late PTS 
following immediate (<24hr), early (24hr-7d), or late seizures (>7d) versus no seizure activity 
prior to discharge from acute hospitalization was also examined. 
Results: PTS incidence during acute hospitalization was highest immediately (<24hrs) after 
injury (8.9%). New onset PTS incidence was greatest between discharge from inpatient 
rehabilitation and Year-1 (9.2%). Late PTS prevalence from injury to Year-1 was 11.9% and 
reached 20.5% by Year-5. The RR of late PTS was significantly greater for individuals self-
identifying as a race other than black or white at Year-1 (RR=1.96), and for black individuals at 
Year-5 (RR=2.86) versus white individuals. Late PTS was greater for individuals with certain 
intracranial pathologies (i.e. subarachnoid hemorrhage). Penetrating TBI had even higher RR but 
did not reach significance, likely due to small group size. Individuals with immediate and late 
seizures during acute hospitalization were at a significantly greater late PTS risk (RR: 2.61 and 
3.36, respectively).  
Significance: In this prospective, longitudinal, observational study, incidence rates were similar 
to those in previously published studies. Individuals with immediate and late seizures during 
acute hospitalization are at an increased late PTS risk after hospitalization. Race and intracranial 
 37 
pathologies also influenced RR for late PTS.  Further studies are needed to examine the impact 
of seizure prophylaxis in high-risk subgroups and to delineate possible contributors to race 
associations on long-term seizure outcomes.  
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4.2 INTRODUCTION 
Traumatic brain injury (TBI) is a prevalent public health problem with an annual incidence over 
2.5 million in the United States (US), of which approximately 12% result in hospitalization or 
death 3. TBI also has many related secondary chronic conditions 121 including shorter life-
expectancy after severe TBI versus demographically similar, non-TBI populations 2. Recent 
work using the TBI Model Systems (TBIMS) National Database (NDB) found seizure to be an 
important contributor to premature death among individuals who were hospitalized and received 
inpatient rehabilitation for TBI, who had a 50-fold risk for subsequent seizure related death 
compared to an uninjured similarly matched sample 2.  
Post-traumatic seizures (PTS) can occur any time post-TBI. Classification is based on the 
time of seizure post-injury: immediate (<24hrs), early (24hrs-7d), or late (>7d post-TBI) 41. 
These cut-offs reflect proposed differences in causal mechanisms and subsequent seizure risk 42; 
66. Seizures occurring within the first week following TBI, also termed acute symptomatic 
seizures 43, are considered transient, decreasing seizure threshold only temporarily 42. Late PTS, 
often used interchangeably with post-traumatic epilepsy (PTE), is characterized by persistent 
neurobiological changes, attributed to secondary injury biochemical cascades and epileptogenic 
mechanisms that eventually present as clinical seizures 18; 31. Individuals with acute symptomatic 
seizures who have a subsequent late seizure are considered to have late PTS or PTE. The clinical 
definition of epilepsy, revised in 2014 by the International League Against Epilepsy (ILAE), 
includes conditions where an individual has a single unprovoked seizure and their risk of a 
recurrent seizure is similar to, or greater than, the risk of seizure recurrence after two unprovoked 
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seizures occurring ≥24hrs apart (≥60%) 42.  The recurrent seizure risk following a single, 
unprovoked seizure >7d post-TBI is high enough to consider late PTS as an epileptic condition 
42; 56. For the current study, late PTS is used, but is equivalent to the current definition of PTE. 
Reported PTS incidence varies widely and depends on study design and population 
characteristics. Few large epidemiological PTS investigations have been conducted in 
heterogeneous populations. The seminal population-based study in the US examined late PTS in 
a predominantly white population from 1935 to 1984 12. Among individuals with severe TBI, the 
cumulative probability of late PTS was 10.0% five years after TBI; early PTS occurred in 2.6% 
of individuals 12. This study included all ranges of TBI severity, was racially homogenous, and 
included both adults and children. Inclusion of adults and children may confound risk 
relationships and complicate accurate risk factor determination since neurological 
injury/recovery mechanisms post-TBI may vary over the course of neural development or aging. 
These authors also reported 10.3% of adults with severe TBI developed early PTS 63. Other, 
smaller studies report early PTS incidence to range from 2.4 to 8.4% 66; 122. However, these 
studies included children and adults with a range of TBI severities. Late PTS cumulative 
probability rates have been more often reported and findings vary widely 12; 47; with prevalence 
ranging from 4%-19% 12; 66; 67; 70; 123. While these studies provide important information 
regarding PTS frequency after TBI, many are retrospective, not racially diverse, from single 
medical centers, and cannot be generalized to large heterogeneous populations. Additionally, 
they provide little information on immediate and/or early PTS. To address these limitations, the 
purpose of the current study was to prospectively determine the incidence of PTS following TBI 
among individuals with moderate-to-severe TBI requiring rehabilitation and surviving at least 5 
years using a large-scale, multi-center database. 
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We used the TBIMS-NDB to calculate multiple PTS frequency measures in a cohort 
followed out to five years post-injury. Additionally, we stratified PTS incidence at various time-
points by demographic and injury characteristics of interest to compute relative risk (RR) for 
each factor.  
4.3 METHODS 
4.3.1 Study Design and Population 
Data were obtained from the prospective TBIMS-NDB. The TBIMS-NDB is a multi-
center, prospective, observational study to investigate recovery and outcomes following acute 
neurotrauma and inpatient rehabilitation in a heterogeneous population of individuals with 
moderate-to-severe TBI, across the US. All participating sites have an affiliated trauma center 
with acute neurosurgical capabilities and associated comprehensive inpatient rehabilitation. 
Eligibility criteria are: moderate-to-severe TBI (PTA>24hrs, or LOC>30minutes, or emergency 
department GCS<13, or positive neuroimaging findings), age ≥16yrs, admitted to a participating 
hospital emergency department within 24hrs of injury, and received both acute care and inpatient 
rehabilitation within a TBIMS designated hospital system. All enrolled individuals, or legal 
proxy, provided written informed consent; Institutional Review Board approval exists at all sites.   
An additional inclusion criterion for this study was completion of Year-5 post-injury 
follow-up interview. Further, individuals were then excluded if data regarding seizure activity 
during acute care hospitalization, or Year-1 and Year-2 post-injury, were not available. The 
acute hospitalization seizure variable was dropped from TBIMS data collection procedures, and 
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follow-up seizure definitions changed, in 2003 and 2005, respectively. Therefore, all individuals 
included in analyses were enrolled between 1989 and 2000; follow-up assessments were 
completed by 2006. 
4.3.2 Data Collection 
Data were collected at enrollment, Year-1, Year-2, and Year-5 post-injury. Enrollment 
data included demographic, social, and injury characteristics as well as personal and medical 
history (pre-injury), and acute outcomes. A proxy interview was completed, for both enrollment 
and follow-up when participants with TBI were unable to answer questions accurately. 
Throughout the study duration, data collection protocols changed over time. Therefore, missing 
data may exist even for individuals who completed assessments at all study time-points.   
Outcome Variable 
The main outcome variable was PTS status, determined during the course of acute care 
hospitalization and at each follow-up time-point (Year-1, Year-2, and Year-5).  
4.3.3 PTS During Acute Care Hospitalization 
The presence/absence of a physician-confirmed clinical seizure during acute 
hospitalization was identified via medical record review using a standardized form and classified 
based on time from injury (immediate: <24hrs, early: 1-7days, late: >7days). Only time of first 
seizure was recorded. Multiple seizures were not captured, therefore, an individual seizing 
immediately or early after injury may have also seized in a subsequent time category prior to 
acute discharge.  
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4.3.4 PTS at Follow-up Interviews 
At each follow-up, individuals were asked “Have you been told by a physician that you 
have had a seizure since your last follow-up?”. Yes/No answers were recorded; individuals self-
reporting seizure activity were documented as having PTS at the specified time-point.  
4.3.5 PTS Risk Factors  
Risk factors of interest included demographic and injury characteristics. Demographic 
variables included age, sex, and race. Injury characteristics included admission Glasgow Coma 
Scale (GCS) score, pathology on computed tomography (CT) scan obtained within 7 days of 
injury, and penetrating TBI (pTBI; Supplemental Table 1). Injury severity was also classified 
using alternate criteria for moderate-to-severe injury based on duration of post-traumatic amnesia 
(PTA), loss of consciousness (LOC), and positive neuroimaging findings124. CT findings were 
included as separate variables for specific pathology type [e.g., subdural hematoma (SDH), 
subarachnoid hemorrhage (SAH)] coded as present/absent, and were not mutually exclusive. 
pTBI was computed via a coding algorithm previously validated in a subsample of the TBIMS85. 
A contusion load score was calculated by summing the number of regions with contusion on CT 
reports, then collapsing the sum into 0, 1, 2, 3, and 4 or more regions. Seizures during acute 
hospitalization were examined as PTS risk factors at follow-up (Supplemental Table 1). No 
data were collected on premorbid seizure activity or history of epilepsy. ICD-9 codes indicating 
neurosurgical procedures or complications were not collected, nor were medication data.  
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4.3.6 Statistical Analysis 
All statistical analyses were completed using SAS version 9.4 (SAS Institute, Carry NC) 
and R version 3.0.2 125. Seizure incidence was calculated during acute care hospitalization and at 
follow-up. At Year-1 and Year-2, if data on seizure activity since last follow-up were missing 
(n=101 and n=99, respectively), seizure status was considered not present at that time-point. If 
individuals had no prior seizure activity, they were considered “at-risk” for PTS and were 
included in the denominator of incidence calculations. If individuals had evidence of PTS at a 
previous time-point, they were not considered “at-risk” for incident PTS. Sensitivity analyses, 
including Chi-Square and Mann-Whitney, or Fisher’s Exact test and Kruskal-Wallis, were 
conducted to determine whether individuals with missing data at Year-1 or Year-2 differed from 
those without missing data. Late PTS incidence since last follow-up was calculated at Years-1, 2, 
and 5. Late PTS prevalence from time-of-injury was also calculated at each follow-up time-point 
(i.e. >7d to Year-1, >7d to Year-2, etc.). Additionally, the percent of individuals reporting 
seizure activity at multiple time-points was calculated, stratified by time of onset.  
Following primary incidence calculations, immediate/early PTS (injury to 7 days), late 
PTS from injury to Year-1, and late PTS from Year-1 to Year-5 incidence rates were stratified by 
risk factors of interest. For demographic variables identified as having significantly different RR 
of PTS, sensitivity analyses were conducted to determine if there were differences in injury 
characteristics.  
Seizures during acute care (immediate, early, late) were then examined specifically as 
risk factors. Prior to this analysis, late PTS was recalculated to remove late seizures during acute 
care (>7days to discharge) from the case definition in order to evaluate RR for late PTS at Year-
1 and Year-5 follow-up.   
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4.4 RESULTS 
4.4.1 Population 
Data were available for 2,418 individuals injured and enrolled prior to 2001. Of these, 
796 were assessed at 5-years post-injury and met inclusion criteria for this analysis (Figure 1). 
Individuals were predominantly male (74.8%), self-identified as white (58.3%), and tended to be 
in their mid-thirties at time of injury. The predominant cause of injury was motor vehicle 
collision (51.6%) (Table 1). Individuals lost to follow-up at Year-1 or Year-2 who were 
recaptured at Year-5 tended to have less severe injuries and fewer high-risk pathologies (data not 
shown). 
4.4.2 Frequency Measures 
By the Year-5 follow-up, 219 (27.5%) individuals had reported or documented seizure 
activity at some point post-injury and 163 (20.5%) developed late PTS (Table 2). During acute 
care hospitalization (mean=22.8 days), 98 (12.3%) individuals seized, with highest acute 
hospitalization PTS incidence immediately (<24hrs) after TBI (Table 2). 1.8% of individuals 
developed incident PTS after 7d post-injury but prior to acute discharge. Incidence of new onset 
and late PTS since last follow-up peaked at Year-1 (Table 2). Of all individuals developing late 
PTS by Year-5, 58.3% did so by Year-1, and 82.2% did so by Year-2. Further, at Years-1, 2, and 
5, more than 50% of individuals reporting seizure activity endorsed multiple seizures since last 
queried.  
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Of individuals first seizing prior to Year-5, 38.0% reported seizure activity at one time 
interval only. Among individuals with incident PTS at Year-1 or Year-2, 64% and 40.1% 
respectively, reported interval seizure activity at subsequent follow-up(s) (Supplemental Table 
2).  
4.4.3 Stratified Incidence and Relative Risks 
Stratified analyses showed PTS incidence was nominally lower among women than men 
at each time-point, but RR did not reach significance. Individuals self-identifying as white also 
tended to have lower RR of PTS versus individuals who did not identify as white with significant 
differences evident at Year-1 and Year-5. Although individuals age 35-44 at injury had greater 
risk of PTS at Year-5, no consistent pattern was seen (Table 3a). Sensitivity analyses showed 
differences in pTBI frequencies across race [2.4% white, 7.7% black, 6.3% other with pTBI 
(p=0.01)]. 
Immediate/early PTS incidence stratification by pathology showed no patterns. When late 
PTS incidence was stratified by pathology, RR was nominally greater for individuals with each 
pathology examined versus those without the given pathology, except for intra-ventricular 
hemorrhage at Year-1. Highest nominal incidence was observed for individuals with pTBI at 
both Year-1 and Year-5. Despite these patterns, only the RR for SAH pathology (Table 3b) and 
contusion load at Year-1 reached significance (Table 3c).  
PTS incidence was stratified by two measures of injury severity: GCS, and moderate 
versus severe injury as determined by duration of LOC, PTA, and neuroimaging findings. 
Although RR was not significantly greater for individuals with more severe TBI as classified by 
these measures (Table 3c), late PTS incidence at Year-5 was nominally greater for individuals 
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with more severe. When late PTS incidence at Year-1 and Year-5 were stratified by time of 
seizure during acute hospitalization, significant RR’s were found (Table 4). Individuals with 
immediate/late seizures occurring during acute care were more than twice as likely (RR: 2.61 
and 3.36, respectively) to develop late PTS between acute discharge and Year-1. Those with 
immediate seizures also had higher risk (RR=2.06) at Year-5. 
4.5 DISCUSSION 
We examined multiple PTS frequency measures and associations with demographic and injury 
characteristics during and following acute care hospitalization and inpatient rehabilitation for 
moderate-to-severe TBI from a prospectively followed, large, nation-wide sample. Total PTS 
incidence during acute hospitalization was slightly higher than previously reported, but incidence 
of early seizure was consistent with previous reports 12; 48; 50; 65; 80; 122; 126. However, not all prior 
PTS studies during acute hospitalization clarify if immediate and early seizures are considered 
simultaneously. Few previous reports specifically delineate immediate PTS incidence. Annegers 
and colleagues determined 2.1% of a Rochester county Minnesota study cohort, including 
children and all injury severities injured from 1935-1974, developed early PTS 63. Of these, 
75.9% first seized during the initial 24hrs post-TBI, similar to our finding that 72.4% of 
individuals who developed PTS during acute hospitalization first seized within 24hrs of injury. 
These rates are higher than those reported earlier by Jennett, where only 5% of the cohort 
exhibited early seizures with 60% occurring within 24hrs 50. Disparate study findings might be 
due to differences in participants (i.e., injury severity/age) or methods for capturing 
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immediate/early PTS. When considering only adults with severe TBI in Annegers’ study, 10.3% 
developed early seizures63, similar to 10.7% in our study.   
Interval new onset seizure (9.2%) and late PTS (10.8%) incidence were highest at Year-1, 
similar to previously published findings in comparable study samples 66. Annual late PTS 
incidence since last follow-up at Year-1 and Year-2 (10.8 and 5.5%, respectively) were higher 
than annual incidence rates previously reported by Ferguson et al 69. In our study, late PTS 
prevalence from injury to Year-1 (11.9%) and Year-5 (20.5%) were ≥2 times higher than for 
those with severe TBI in Annegers’ study 12. In two studies by Englander and colleagues, using a 
sample very similar to ours, late PTS incidence at 2 years was 16.4 and 14% 47; 127, similar to the 
16.8% in our study. Differences between the percent affected in our analyses may be attributed 
to the inclusion of individuals with mild TBI or children. Possible differences between our 
analysis and Annegers’ work could also be attributed to differences in study design (e.g. 
population-based study with medical chart review vs. prospective longitudinal cohort study and 
self-report). Additionally, due to changes in clinical care over time, differences could also be 
attributed to increased EEG monitoring of individuals post-TBI, and/or higher survival of the 
more severely injured in the current study. Future research validating these findings, using a 
more recent cohort from TBIMS-NDB could be considered with reintroduction of seizure data 
collection. However, due to changes in TBIMS seizure data collection occurring after 2000, we 
currently cannot validate the distinct effects of acute symptomatic seizures or late seizures during 
acute hospitalization in a more recent, independent TBIMS population. 
Consistent with other studies, 82.2% of individuals developing late PTS did so by Year-2 
post-injury 56. Yet, it is important to recognize new onset seizures, and subsequently new cases 
of late PTS, continued to be detected at Year-5. Previous PTE studies show new cases may 
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develop as many as 30 years post-injury, and epilepsy risk remains significantly elevated versus 
the general population up to 10 years post-injury among those with severe TBI 12. Our data 
provide a more complete picture of the extended risk of late PTS, past the first 1-3 years post-
TBI, when other modern observational cohort studies truncate their follow-up 47; 67; 69. Future 
work should continue to use the TBIMS-NDB to extend the current follow-up time (earliest 
participants now at Year-25 post-injury) and determine if current standardized incidence ratios 
remain similar to or are greater than those found by Annegers.  
Late PTS prevalence reached 20.5% by Year-5. This figure is greater than reported rates 
of 13.7% by 5 years post-injury 66 but remains lower than rates in combat veteran populations 72. 
Although both studies’ cohorts were recruited from rehabilitation facilities, differences in study 
design and population (e.g., higher pTBI among military populations) likely contributed to 
differences.   
When PTS incidence was stratified by risk variables, RR patterns were observed for race, 
but not sex. The lack of significantly greater RR for men could be confounded by survival bias, 
if men were more severely injured and did not survive to Year-5. However, in a more recently 
injured TBIMS-NDB cohort, men were at higher risk for seizures during acute care 
hospitalization, even in multivariable models including markers of injury severity (Manuscript 
Two). Individuals self-identifying as white had a lower late PTS risk at both Year-1 and Year-5 
versus non-white individuals. No other known large epidemiological PTS studies have reported 
significant differences in risk associated with race. One study demonstrated increased RR of late 
PTS at 2 years for non-white groups versus white individuals, but results were not statistically 
significant 47. Differences in PTS frequency by race may be partially explained by differences in 
injury type (i.e. pTBI). Although, previous work developing prognostic models of PTS using a 
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more recent cohort from the TBIMS-NDB did not find race to be even nominally associated with 
PTS and subsequently did not investigate race as a PTS predictor in multivariable modeling 
(Manuscript Two). In addition to more frequent pTBI, differences in late PTS risk by race may 
reflect differences in environmental exposure (e.g. repeat TBI, substance use) 128 as well as 
known racial differences in allelic frequencies for genes thought to influence PTS risk 94; 102; 103; 
129. Future work might investigate racial/ethnic differences in epilepsy related outcomes and 
comorbid burden 130. 
Examining incidence stratified by pathology revealed somewhat surprising result. While 
patterns of nominal rates were as expected, late PTS risk was only significantly elevated for SAH 
and higher contusional loads at Year-1. These data are inconsistent with most studies, which find 
that SDH is a significant PTS risk factor. Our findings may be due to variability within SDH and 
SAH definitions applied in the TBIMS-NDB over time. Due to other limitations in data capture, 
we cannot examine incidence stratified by other potential risk factors of interest like 
neurosurgical procedures.  
Of special note, at Years-1 and 5, pTBI was associated with the highest nominal late PTS 
RR of any characteristic studied (18.5 and 18.2%, respectively). Differences in RR were not 
statistically significant, but the low numbers with pTBI suggests these analyses were 
underpowered. Additionally, we did not observe consistent increases in PTS incidence with 
greater injury severity based on GCS or alternative criteria.  
When late PTS incidence at Year-1 and Year-5 were recalculated without individuals 
seizing late during acute hospitalization included in the case definition, there were significant 
differences in RR based on timing of first acute seizure. Individuals with immediate seizure 
(<24hrs) had a higher late PTS incidence and greater risk at both time-points versus those not 
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seizing during acute hospitalization. Those with late seizures (>7d) during acute hospitalization 
also had a higher late PTS incidence at Year-1 versus individuals not seizing acutely (Table 4). 
Surprisingly, having acute seizure(s) restricted between 1-7 days did not increase late PTS risk. 
Multiple reports document that early seizure increases late PTS risk 12; 47; 66; 69; 70. However, these 
studies do not differentiate between immediate and early seizures. Previous work by Temkin 
demonstrated increased early seizure risk associated with immediate seizures, but early seizures 
(1-7 days) were associated with increased late PTS risk 78. Unlike Temkin’s work, we did not 
observe increased late PTS risk associations with early seizures. It is unclear in Temkin’s work 
whether individuals with early seizures seized immediately or not, and how selecting individuals 
at high risk of PTS for inclusion impacted late PTS findings. In our analyses, immediate/early 
seizures were mutually exclusive; therefore, we could not examine the impact of seizing both 
immediately and early on late PTS risk.  
The high percentage of individuals in our study seizing immediately, along with the 
common use of early PTS prophylaxis after phenytoin was shown in clinical trials to reduce 
early seizures 131, may complicate observed relationships between immediate/early seizures and 
late PTS reported in our study. Even if seizure prophylaxis was administered immediately upon 
admission, it is likely that individuals could have already experienced their first immediate 
seizure 50. Our data demonstrate lower incidence of early versus immediate seizure and show 
immediate seizure (but not early seizure) significantly increases late PTS risk out to Year-5. 
However, seizure prophylaxis during the first week post-injury is shown to only have beneficial 
effects in reducing early PTS, not late PTS 131. While not directly measured in the TBIMS-NDB, 
data from a single TBIMS center from 2000-2007 show 96% received some form of AED 
prophylaxis during their acute care 102. Taken together, we hypothesize that early PTS 
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prophylaxis reduces early seizures but does not reduce the epileptogenic processes initiated by 
immediate seizures that may (often) occur prior to prophylaxis administration. Therefore, we 
speculate that individuals in our study who may have seized prior to appropriate prophylaxis use 
may remain at-risk for late PTS. Future work needs to examine late PTS risk specifically among 
individuals receiving prophylaxis but who seized prior to or during AED loading, as these data 
may reshape PTS prophylaxis guidelines. We suggest that antecedent, immediate/early seizure 
activity can over-activate excitatory amino acid (EAA) receptors 18, perpetuating TBI induced 
excitotoxicity and contributing to epileptogenesis, regardless of early PTS prophylaxis 6.  
While these data provide PTS characterization in a large cohort of individuals from the 
US, limitations must be considered. Our cohort is restricted to individuals having received 
inpatient rehabilitation and surviving to Year-5 post-TBI. Additionally, PTS and/or PTE 
definitions and data collection methods used can bias descriptive analyses. We cannot specify the 
data source used as evidence of seizure during acute hospitalization other than to cite 
“documentation from the medical record”. It is unclear if evidence was collected using 
electroencephelogram (EEG). Currently, continuous EEG (cEEG) is common in many trauma 
centers, and its use identifying subclinical seizures may result in higher incidence of acute 
symptomatic seizures. How cEEG might have factored into acute symptomatic seizure 
identification for individuals injured prior to 2001 is less certain. In critically ill patients with 
TBI, up to 50% of seizures are reported to be subclinical 76. Additionally, only the first seizure 
during acute care hospitalization was documented. Therefore, individuals seizing immediately or 
early, and having later seizures during acute hospitalization, were not accounted for in late PTS 
calculations if they did not experience a seizure after discharge from acute hospitalization. 
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Similarly, subsequent seizures during acute care hospitalization if occurring, were not 
documented.  
Another potential limitation is PTS misclassification at follow-up because, while acute 
symptomatic seizure information was obtained via medical record, all follow-up data were based 
on participant or proxy self-report of whether a physician told them they had a seizure. 
Individuals could over-report if they experienced psychogenic non-epileptic seizures or transient 
neurological symptoms not due to seizure activity. Conversely, individuals experiencing true 
epileptic seizure activity between follow-ups, who were not aware or did not seek care, may 
contribute to underestimation of the true number of individuals with late PTS. Nevertheless, in 
large epidemiological studies of seizure and epilepsy, self-report remains common and necessary 
132. Adding to possible misclassification bias, individuals with missing data at Year-1 or Year-2 
were included as at-risk individuals for incidence calculations. By doing so, we may have 
included individuals as “at-risk” who had seized, underestimating the true incidence. However, 
we examined individuals with missing data and determined they typically had less severe injury 
and less intracranial pathology identified via CT than those returning for all follow-ups (data not 
shown). Within the larger TBIMS-NDB, individuals with less severe TBI who presumably 
recover better, are more often lost to follow-up than individuals with more complex injuries and 
presumably worse outcomes 133. Therefore, excluding individuals with missing data at Year-1 or 
Year-2, who were subsequently followed at Year-5, would have likely produced a greater degree 
of bias and overestimated incidence of PTS. Due to limitations in data collection, we were 
unable to identify, and subsequently exclude, individuals with pre-existing epilepsy disorders. 
Despite these limitations, the current analyses suggest race as a possible PTS risk factor. The 
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work also provides insight into temporal PTS risk factors, including immediate/early seizure, and 
examines the effect of each on late PTS incidence out to 5 years post-injury. 
4.6 TABLES 
Table 5. Demographic and Injury Characteristics at Baseline Visit N(%) 
Sample Size = 796 
Age at Injury* 35.4 (15.7) 
Sex  Male 595 (74.8) 
Female 201 (25.2) 
Race  White 464 (58.3) 
Black 246 (30.9) 
Other 86 (10.8) 
Cause of Injury  
MVA 411 (51.6) 
Fall 109 (13.7) 
Any 
Violence 164 (20.6) 
Any Sport 9 (1.1) 
Other 103 (12.9) 
Injury Severity Moderate 79 (9.9) Severe 717 (90.1) 
PTA (days)* 31.6 (26.3) 
LOC (days)* 10.7 (18.9) 
Admission DRS* 13.3 (5.4) 
Length of Acute Stay (days)* 22.8 (19.4) 
*mean(SD); PTA – Post-Traumatic Amnesia; 
LOC – Loss of Consciousness; DRS – 
Disability Rating Scale 
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Table 6. Frequency Measures of PTS at Follow-up Time Points after TBI 
 
Incidence of 
New Onset 
Seizure 
Incidence of Late 
PTS since last 
follow-up* 
Prevalence of 
Late PTS since 
injury 
Time Point N (%) N (%) N (%) 
Initial Population 796 796 796 
Acute 
Seizure 
Status 
Immediate 
(<24hrs) 71 (8.9) --- --- 
Early  
(1 < 7 days) 14 (1.9) --- --- 
Late  
(>7 days) 13 (1.8) --- --- 
Year 1 64 (9.2) 86 (10.8) 95 (11.9) 
Year 2 32 (5.0) 39 (5.5) 134 (16.8) 
Year 5 25 (4.2) 29 (4.3) 163 (20.5) 
*Year-1 represents late PTS incidence since discharge from rehab 
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Table 7. Incidence and Relative Risk of PTS Stratified by Variables of Interest 
  Immediate and Early PTS Late PTS Year 1 Late PTS Year 5 
  N(%) RR (CI) N(%) RR (CI) N(%) RR (CI) 
  No 
Seizure Seizure  
No 
Seizure Seizure  
No 
Seizure Seizure  
N (%) 711 
(89.3) 
85 
(10.7)  
701 
(88.1) 
95 
(11.9)  
633 
(90.3) 
68 
(9.7)  
Se
x 
Male 531 (89.6) 
64 
(10.8) 1.0 
519 
(87.2) 
76 
(12.8) 1.0 
466 
(89.8) 
53 
(10.2) 1.0 
Female 180 (89.2) 
21 
(10.4) 
0.97 
(0.61-1.55) 
182 
(90.6) 
19 
(9.4) 
0.74 
(0.46-1.19) 
167 
(91.8) 
15 
(8.2) 
0.81 
(0.47-1.40) 
R
ac
e White 
416 
(89.7) 
48 
(10.3) 1.0 
420 
(90.5) 
44 
(9.5) 1.0 
395 
(94.1) 
25 
(5.9) 1.0 
Black 218 (88.6) 
28 
(11.4) 
1.10 
(0.71-1.71) 
211 
(85.8) 
35 
(14.2) 
1.50 
(0.99-2.27) 
175 
(82.9) 
36 
(17.1) 
2.86 
(1.77-4.64) 
Other 77 (89.5) 
9 
(10.5) 
1.0 
(0.52-1.98) 
70 
(81.4) 
16 
(18.6) 
1.96 
(1.16-3.31) 
63 
(90.0) 
7 
(10.0) 
1.68 
(0.76-3.74) 
A
ge
 
15-24 224 (88.5) 
29 
(11.5) 1.0 
219 
(86.6) 
34 
(13.4) 1.0 
204 
(93.2) 
15 
(6.8) 1.0 
25-34 165 (90.7) 
17 
(9.3) 
0.81 
(0.46-1.44) 
162 
(89.0) 
20 
(11.0) 
0.82 
(0.49-1.37) 
145 
(89.5) 
17 
(10.5) 
1.53 
(0.79-2.98) 
35-44 150 (89.3) 
18 
(10.7) 
0.93 
(0.54-1.63) 
146 
(86.9) 
22 
(13.1) 
0.97 
(0.59-1.61) 
122 
(83.6) 
24 
(16.4) 
2.40 
(1.30-4.42) 
45-54 87 (91.6) 
8 
(8.4) 
0.73 
(0.35-1.55) 
83 
(87.4) 
12 
(12.6) 
0.94 
(0.51-1.74) 
75 
(90.4) 
8 
(9.6) 
1.40 
(0.62-3.20) 
55-64 37 (80.4) 
9 
(19.6) 
1.71 
(0.87-3.36) 
40 
(87.0) 
6 
(13.0) 
0.97 
(0.43-2.18) 
37 
(82.5) 
3 
(7.5) 
1.10 
(0.33-3.61) 
65+ 48 (92.3) 
4 
(7.7) 
0.67 
(0.25-1.83) 
51 
(98.1) 
1 
(1.9) 
0.14 
(0.02-1.02) 
50 
(98.0) 
1 
(2.0) 
0.29 
(0.04-2.12) 
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Table 8. Incidence and Relative Risk of PTS Stratified by Variables of Interest 
  Immediate/Early PTS Late PTS Year 1 Late PTS Year 5 
  N(%) RR (CI) N(%) RR (CI) N(%) RR (CI) 
  No Seizure Seizure  
No 
Seizure Seizure  
No 
Seizure Seizure  
SD
H
 
No 350 (88.4) 
46 
(11.6) 1.0 
357 
(90.2) 
39 
(9.8) 1.0 
332 
(93.0) 
25 
(7.0) 1.0 
Ye
s 
224 
(92.2) 
19 
(7.8) 
0.67 
(0.40-1.12) 
209 
(86.0) 
34 
(14.0) 
1.42 
(0.92-2.19) 
188 
(90.0) 
21 
(10.0) 
1.43 
(0.82-2.50) 
SA
H
 
No 323 (89.0) 
40 
(11.0) 1.0 
333 
(91.7) 
30 
(8.3) 1.0 
306 
(91.9) 
27 
(8.1) 1.0 
Ye
s 
251 
(90.9) 
25 
(9.1) 
0.82 
(0.51-1.32) 
233 
(84.4) 
43 
(15.6) 
1.89 
(1.22-2.92) 
214 
(91.9) 
19 
(8.2) 
1.00 
(0.57-1.77) 
IV
H
 
No 452 (89.2) 
55 
(10.8) 1.0 
448 
(88.4) 
59 
(11.6) 1.0 
413 
(92.2) 
35 
(7.8) 1.0 
Ye
s 
122 
(92.4) 
10 
(7.6) 
0.70 
(0.37-1.33) 
118 
(89.4) 
14 
(10.6) 
0.91 
(0.53-1.58) 
107 
(90.7) 
11 
(9.3) 
1.19 
(0.63-2.28) 
ED
H
 No 
503 
(90.5) 
53 
(9.5) 1.0 
497 
(89.4) 
59 
(10.6) 1.0 
457 
(92.0) 
40 
(8.1) 1.0 
Ye
s 
71 
(85.5) 
12 
(14.5) 
1.52 
(0.85-2.72) 
69 
(83.1) 
14 
(16.9) 
1.59 
(0.93-2.71) 
63 
(91.3) 
6 
(8.7) 
1.08 
(0.48-2.45) 
pT
B
I 
No 531 (89.7) 
61 
(10.3) 1.0 
525 
(88.7) 
67 
(11.3) 1.0 
485 
(92.4) 
40 
(7.6) 1.0 
Ye
s 
25 
(92.6) 
2 
(7.4) 
0.72 
(0.19-2.79) 
22 
(81.5) 
5 
(18.5) 
1.64 
(0.72-3.73) 
18 
(81.8) 
4 
(18.2) 
2.39 
(0.94-6.08) 
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Table 9. Incidence and Relative Risk of PTS Stratified by Variables of Interest 
  Immediate/Early PTS Late PTS Year 1 Late PTS Year 5 
  N(%) RR (CI) N(%) RR (CI) No Seizure RR (CI) 
  
No 
Seizure 
Seizure  
No 
Seizure 
Seizure  
No 
Seizure 
Seizure  
C
on
tu
si
on
 L
oa
d 
0 230 (88.5) 
30 
(11.5) 1.0 
238 
(91.5) 
22 
(8.5) 1.0 
222 
(93.3) 
16 
 (6.7) 1.0 
1 99 (90.0) 
11 
(10.0) 
0.87 
(0.45-1.67) 
101 
(91.8) 
9 
(8.2) 
0.97 
(0.46-2.03) 
96 
(95.1) 
5 
(4.9) 
0.74 
(0.28-1.96) 
2 126 (92.0) 11 (8.0) 
0.70 
(0.36-1.35) 
117 
(85.4) 
20 
(14.6) 
1.73 
(0.98-3.05) 
104 
(88.9) 
13 
(11.1) 
1.65 
(0.82-3.32) 
3 57 (86.4) 9 (13.6) 
1.18 
(0.59-2.37) 
56 
(84.9) 
10 
(15.1) 
1.79 
(0.89-3.60) 
50 
(89.3) 
6  
(10.7) 
1.59 
(0.65-3.89) 
>=4 62 (93.9) 
4 
(6.1) 
0.53 
(0.19-1.44) 
54 
(81.8) 
12 
(18.2) 
2.15 
(1.12-4.11) 
48 
(88.9) 
6  
(11.1) 
1.65 
(0.68-4.03) 
In
ju
ry
 
Se
ve
rit
y
* 
Mod 69 (87.3) 
10 
(12.7) 1.0 
69 
(87.3) 
10 
(12.7) 1.0 
63 
(91.3) 
6 
(8.7) 1.0 
Sever
e 
642 
(89.5) 
75 
(10.5) 
0.83 
(0.45-1.53) 
632 
(88.2) 
85 
(11.8) 
0.94 
(0.51-1.73) 
570 
(90.2) 
62 
 (9.8) 
1.13 
(0.51-2.51) 
G
C
S 
>13 169 (88.5) 
22 
(11.5) 1.0 
172 
(90.1) 
19 
(9.9) 1.0 
158 
(91.9) 
14 
 (8.1) 1.0 
9-12 113 (86.9) 
17 
(13.1) 
1.14 
(0.63-2.05) 
113 
(86.9) 
17 
(13.1) 
1.31 
(0.71-2.43) 
105 
(92.9) 
8 
(7.1) 
0.87 
(0.38-2.01) 
8 347 (90.4) 
37 
(9.6) 
0.84 
(0.51-1.38) 
334 
(87.0) 
50 
(13.0) 
1.31 
(0.79-2.16) 
296 
(88.6) 
38 
(11.4) 
1.40 
(0.78-2.51) 
*Injury severity as determined by GCS, duration of loss of consciousness and post-traumatic amnesia, and 
neuroimaging findings 
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Table 10. Incidence and Relative Risk of Late PTS* Stratified by Variables of Interest 
Acute 
Seizure 
Status 
Late PTS Year 1 Late PTS Year 5 
N(%) RR (CI) N(%) RR (CI) 
No 
Seizure Seizure  
No 
Seizure Seizure  
710 
(89.2) 
86 
(10.8)  
641 
(90.3) 
69 
(9.7)  
None 634 (90.8) 
64 
(9.2) 1.0 
577 
(91.0) 
57 
(9.0) 1.0 
Immediate 54 (76.1) 
17 
(23.9) 
2.61 
(1.62-4.20) 
44 
(81.5) 
10 
(18.5) 
2.06 
(1.12-3.78) 
Early 13 (92.9) 
1 
(7.1) 
0.78 
(0.12-5.22) 
12 
(92.3) 
1 
(7.7) 
0.86 
(0.13-5.72) 
Late 9 (69.2) 
4 
(30.8) 
3.36 
(1.44-7.84) 8 (88.9) 
1 
(11.1) 
1.24 
(0.19-7.97) 
*No seizures during acute hospitalization (including late) contribute to 
definition of late PTS 
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Table 11. Supplemental Table: Definitions of Risk Factors for Stratified Incidence 
 Variable Definition Method 
Demographics 
Sex Biological sex  
Race Self-identified race Self-report 
Age Age categorized into 10 year 
increments, beginning at age 15 and 
ending with those 65 and older 
Medical 
Record 
Review 
Injury 
Characteristics 
Injury Severity Moderate: normal or abnormal 
imaging with 30min <LOC< 24 hours, 
or 1day<PTA<7days, or GCS 9-12 
Severe: normal or abnormal imaging 
with LOC >24 hours, or PTA>7days, 
or GCS 3-8 
Medical 
Record 
Review 
Subdural Hematoma 
(SDH) 
Presence of extra-axial collection 
within sub-dural space including 
hematoma and hygroma 
Medical 
Record 
Review 
Subarachnoid 
Hemorrhage (SAH) 
Blood in ambient, basal, 
interpenduncular cisterns or cisterna 
magna, or along falx or tentorium 
Medical 
Record 
Review 
Intra-ventricular 
Hemorrhage (IVH) 
Blood documented within intra-
ventricular space 
Medical 
Record 
Review 
Epidural Hematoma 
(EDH) 
Presence of extra-axial collection 
within epidural space 
Medical 
Record 
Review 
Contusion Load Based on medical record review. 
Calculated by summing the number of 
regions with parenchymal contusions 
documented in medical record. 
Regions were specified by cortical area 
or non-cortical focal contusion. A 
maximum of 6 regions were 
documented (frontal, temporal, 
parietal, occipital, focal non-cortical, 
not specified) 
Calculated 
Variable 
Penetrating TBI Calculated using validated algorithm 
using imaging reports of retained 
fragment and mechanism of injury 
from medical record review. 
Calculated 
Variable 
Seizure during Acute 
Care Hospitalization 
Documents time of first seizure during 
acute care hospitalization (no seizure, 
immediate, early, late). Seizure must 
be confirmed by a physician.  
Medical 
Record 
Review 
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Table 12. Supplemental Table: Individuals Reporting Seizures at Multiple Time Points 
Time of First Seizure (N) Seizure at 1 
Time Point 
Seizure at 2 
Time Points 
Seizure at 3 
Time Points 
Seizure at 4 
Time Points 
Acute 
Seizure 
Status 
Immediate (71) 44 (62.0) 15 (21.1) 9 (12.7) 3 (4.2) 
Early (14) 12 (85.7) 2 (14.3) 0 0 
Late (13) 8 (61.5) 1 (7.7) 1 (7.7) 2 (15.4) 
Year 1 (64) 23 (35.9) 26 (40.6) 15 (23.4) NA 
Year 2 (32) 19 (59.9) 13 (40.1) NA NA 
Year 5 (25) 25 (100) NA NA NA 
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Figure 2. Traumatic Brain Injury Model System Five Year Follow-up CONSORT Figure 
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5.1 ABSTRACT 
Objective: Post-traumatic seizures (PTS) are well-recognized acute and chronic complications 
of traumatic brain injury (TBI). Risk factors have been identified, but considerable variability in 
who develops PTS remains. Existing PTS prognostic models are not widely adopted for clinical 
use and do not reflect current trends in injury, diagnosis, or care. We aimed to develop and 
internally validate preliminary prognostic regression models to predict PTS during acute care 
hospitalization, and at Year-1 and Year-2 post-injury.  
Methods: Prognostic models predicting PTS during acute care hospitalization and Year-1 and 
Year-2 post-injury were developed using a recent (TBI 2011-2014) cohort from the TBI Model 
Systems National Database. Potential PTS predictors were selected based on previous literature 
and biological plausibility. Bivariate logistic regression identified variables with a p-value<0.20 
that were used to fit initial prognostic models. Backward-stepwise elimination was used to 
determine reduced prognostic models and to internally validate using 1000 bootstrap samples. Fit 
statistics were calculated, correcting for over-fitting (optimism).   
Results: The prognostic models identified sex, craniotomy, pre-injury mental health 
treatment/psychiatric hospitalization, and pre-injury limitation in 
learning/remembering/concentrating as significant PTS predictors during acute hospitalization. 
Year-1 significant PTS predictors were injury severity, subdural hematoma (SDH), contusion 
load, craniotomy, craniectomy, pre-injury condition-limiting physical activity, mental health 
treatment/psychiatric hospitalization, and incarceration were significant PTS predictors. Year-2 
significant predictors included seizure during acute hospitalization, SDH, intracranial fragment, 
craniectomy, and pre-injury condition-limiting physical activity. Corrected concordance (C) 
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statistics were 0.549, 0.756, and 0.724 for acute hospitalization, Year-1, and Year-2 models, 
respectively.  
Significance: The prognostic model for PTS during acute hospitalization did not discriminate 
well. Year-1 and Year-2 models showed fair to good predictive validity for PTS. Cranial surgery, 
while medically necessary, requires ongoing research regarding potential benefits of increased 
monitoring for signs of epileptogenesis, PTS prophylaxis, and/or rehabilitation/social support. 
Future studies should externally validate models and determine clinical utility. 
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5.2 INTRODUCTION 
Traumatic brain injury (TBI) is a well-recognized public health problem. Over 2.5 million TBIs 
occur annually in the United States 3; approximately 11% require hospitalization, primarily for 
moderate/severe injury. TBI is increasingly recognized as a chronic disease, significantly 
impacting morbidity and mortality 2; 134. As medicine advances, more individuals are expected to 
survive moderate/severe TBI, increasing the number affected by injury-associated complications.  
Post-traumatic seizures (PTS) and epilepsy (PTE) are well-recognized TBI 
complications. PTS can develop at any point after TBI and is classified by time of first seizure 
(immediate: <24hrs, early: 24hrs to 7d, and late: >7d post-TBI). Immediate and early PTS are 
considered directly related to the primary injury. Late seizures are attributed to secondary injury 
cascades and persistent epileptogenic mechanisms and eventually present as clinical seizures 18; 
31. PTS incidence and prevalence vary widely throughout the literature and depend on study 
design (e.g. length of follow-up), population characteristics (e.g. injury severity), and PTS 
definition. Previous reports after primarily closed-head injury indicate a broad range of percent 
affected (early: 1.4-12%; late: 4.4-18.9%) 12; 47; 50; 66; 69; 123. Work using the NIDILRR Traumatic 
Brain Injury Model System (TBIMS) National Database, including individuals with 
predominantly closed-head moderate/severe TBI, demonstrated incidence rates of 8.9% and 
1.9% for immediate and early PTS, respectively (Manuscript One). By 1yr post-injury, 20.4% 
of the cohort reported seizures, and approximately 12% met criteria for late PTS (i.e. PTE). Late 
PTS incidence from injury to 2yrs and injury to 5yrs post-TBI increased to 16.8% and 20.5% 
 66 
(Manuscript One). Seizure risk after severe TBI, beyond 10yrs post-injury, remains 
significantly elevated compared to the general population 12. These data suggest epileptogenesis 
can follow a prolonged course, and TBI related pathology exerts long-term epileptogenic effects.  
Prognostic models can estimate an individual’s risk for developing an outcome of interest 
based on specific characteristics 111. While many studies examined injury characteristics and 
associations with PTS, few have developed prognostic PTS models. Of these, none have been 
integrated into routine clinical practice. Such models were developed decades ago, using small 
samples, and examining probability based on a single risk factor 46; 135. A multivariable 
mathematical model was developed in the 1970’s and validated using datasets from TBI studies 
available at the time 136. However, these prognostic models do not reflect current trends in injury 
severity, TBI detection and treatment, or seizure prophylaxis. Since then, improved 
neuroimaging allows greater specificity when characterizing intracranial pathology. 
Neurosurgical procedures, including craniectomy, are now more common for treatment of 
intracranial pathology. Therefore, new prognostic models reflecting current injury patterns, 
diagnosis, and treatment trends are required if models are to be clinically useful. Accurate PTS 
risk prediction could help define high-risk populations in support of clinical intervention trials. 
Predictive models could also inform clinical algorithms to identify individuals likely to benefit 
from tailored seizure prophylaxis or treatment. 
The TBIMS National Database (TBIMS-ND) is an ongoing, multi-center, longitudinal 
observational study. Currently, there are 16 funded centers collecting demographic, premorbid 
personal and medical history, and injury-specific data upon study enrollment, as well as chronic 
medical conditions, psychosocial, and rehabilitation outcomes. The TBIMS-ND is an excellent 
source of data for prognostic model development involving a variety of TBI-related outcomes for 
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individuals surviving acute injury and receiving inpatient rehabilitation. The purpose of this 
study was to develop and internally validate prognostic models predicting PTS during acute care 
hospitalization, at Year-1, and Year-2 post-injury for a recent cohort in the TBIMS-ND. 
5.3 METHODS 
5.3.1 Study Design and Population 
Data were obtained from the TBIMS-ND. All participating centers have a Level-I or 
Level-II Trauma Center, acute neurosurgical capabilities, and associated comprehensive 
inpatient TBI rehabilitation. Individuals with moderate/severe TBI (PTA>24 hrs, or 
LOC>30minutes, or emergency department GCS<13, or positive neuroimaging findings), 
admitted to a participating hospital emergency department within 72hrs of injury, age ≥16yrs, 
receiving acute care and inpatient rehabilitation within a TBIMS designated hospital system were 
eligible for study inclusion. All subjects, or legal proxy, provided written informed consent.  
Two variables related to follow-up PTS were collected at different times within the 
TBIMS-ND, with the most recent variable added in 2012. To ensure data reflected current 
population trends and standards of care, current analyses included participants injured between 
January 1, 2012 and August 31, 2014.  
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5.3.2 Data Collection 
Data were limited to those collected at enrollment, Year-1, or Year-2 post-injury. All data 
were collected using standardized protocols. Enrollment data, collected though chart review and 
interview included demographic, social, and injury characteristics, pre-injury personal and 
medical history, and acute outcomes. CT scan data were classified by trained raters based on a 
composite of the worst findings on CT scan over the first 7d post-injury. Follow-up data 
collection was completed via telephone or mailed self-administered battery. Proxy interviews 
were completed if an individual with TBI was unable to provide reliable responses.  
5.3.3 Outcome Variable 
PTS status, dichotomized as present or absent, was the main outcome, determined during 
the course of acute hospitalization, at Year-1, and Year-2. Following discharge from acute 
hospitalization, TBIMS Center data collectors record up to 20 ICD-9 codes in the participant’s 
medical chart related to their TBI admission. To determine PTS status during acute 
hospitalization, all recorded acute care ICD-9 codes were reviewed. ICD-9 codes relating to 
convulsion (780.39), PTS (780.33), and epilepsy (345.0x  345.9x) were included as evidence 
of seizure activity following TBI.  
PTS status at Year-1 and Year-2 were determined solely via participant (or proxy) self-
report. Study participants were asked “Have you had a seizure since your TBI?” at follow-up 
interviews. If participants answered yes, they were asked, “Since your discharge from 
rehabilitation, have you had a seizure?” at the Year-1 follow-up interview and, “In the past year, 
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have you had a seizure?” at the Year-2 follow-up interview.  If patients answered yes to the 
second question, they were counted as having PTS at Year-1 and Year-2, respectively.  
5.3.4 Predictors of Interest 
Predictors of interest included baseline demographics, personal and medical history 
information, and injury characteristics. All predictors were selected a priori based on biological 
plausibility and possible risk factors identified in previous literature 12; 47; 48; 66; 69; 70; 78 (Table 1). 
Demographic variables included age, sex, and race. Personal and medical history variables 
included pre-injury: prior moderate/severe TBI, condition significantly limiting physical activity, 
limitation in learning, remembering, or concentrating, substance abuse, mental health treatment, 
psychiatric hospitalization, suicide attempt, military service, and incarceration.  
Injury characteristics included injury severity (Table 1), duration of post-traumatic 
amnesia (PTA) in Year-1 and Year-2 models, confirmed pathology on CT scan, 
intraparenchymal fragment, penetrating TBI (pTBI), craniotomy, craniectomy, and associated 
spinal cord injury. CT findings were included as separate variables for specific pathology type 
[e.g. subdural hematoma (SDH), epidural hematoma (EDH)], coded as present or absent and 
were not mutually exclusive. pTBI was computed via a coding algorithm previously validated in 
a subsample of the TBIMS 85. Also, a contusion load score was calculated by summing the 
number of regions with reported contusion (Table 1). This score was collapsed into 0, 1, 2, 3, 4, 
and 5 or more regions. At Year-1 and Year-2, seizure during acute hospitalization was included 
as a risk factor. No data were collected on premorbid seizure activity or history of epilepsy.  
Prognostic Modeling 
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PTS prognostic models during acute hospitalization, Year-1, and Year-2 were developed 
and internally validated with resampling. For each time-point [PTS during acute hospitalization, 
PTS status since discharge from rehabilitation (Year-1) and PTS status in the past year (Year-2)], 
all potential risk factors described above were examined using bivariate logistic regression. All 
variables with p-value<0.20 were retained for inclusion in model building.  
A saturated regression model, including all variables identified in the above step, was fit 
for each of the three PTS outcomes. After fitting a saturated model, variables were preliminarily 
examined for multicollinearity using Spearman correlation matrices. For each model, retained 
fragment and pTBI were highly collinear (r>0.9); pTBI occurred much less frequently versus 
retained fragment, and therefore, was not included in further prognostic modeling. Premorbid 
history of mental health disorder and premorbid psychiatric hospitalization were also highly 
collinear and were combined to form a four-level categorical variable (no mental health disorder 
or hospitalization; mental health disorder no hospitalization; hospitalization without mental 
health disorder; both mental health disorder and hospitalization). The saturated model was refit, 
and variance inflation factors (VIF) and condition indices were calculated.   
Next, backward (step-down) variable selection was performed with an exit criterion of 
alpha=0.05. The reduced model was internally validated via resampling in an automated process 
using the rms: Regression Modeling Strategies package for R 120.  Specifically, 1,000 bootstrap 
samples were drawn with replacement from the original data such that each bootstrap sample had 
an equal number of observations as the original dataset. In each bootstrap sample, stepwise 
backward elimination with an exit criterion of alpha=0.05, was used to validate the reduced 
model. The C-statistic, a measure of concordance equal to the area under the receiver operating 
characteristic (ROC) curve, was calculated using Somers’ Dxy for the saturated model 118. The C-
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statistic was calculated for the final, reduced model selected from the original data, with and 
without adjustment for optimism.   
All statistical analyses were completed using SAS version 9.4 (SAS Institute, Cary NC) 
and R version 3.0.3 125.  
5.4 RESULTS 
5.4.1 Population 
2,160 participants injured January 1, 2012 through August 21, 2014 had PTS related 
ICD-9 codes during acute hospitalization recorded (Figure 1). Of the 2,160 participants, 1,941 
had data available on all predictors identified in simple logistic regression for seizure during 
acute hospitalization. For Year-1 analyses, 1,164 participants had PTS data, and 1,039 had data 
available for all predictors included in the saturated regression model. For Year-2 analyses, 410 
participants had PTS data, and 375 had data for predictors included in the saturated model. At 
each time point, demographics were similar to previous TBI studies (Table 2).   
5.4.2 Prognostic Models 
Following bivariate examination of predictors, 12 variables met inclusion criteria 
(p<0.20) for the initial, saturated prognostic model for PTS during acute hospitalization (Table 
3). After backward elimination and bootstrapping, the final model included sex, craniotomy, pre-
injury limitation in learning/concentrating/remembering, and preinjury mental health treatment 
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and/or psychiatric hospitalization. Craniotomy was the most statistically significant predictor in 
the final prognostic model and was selected in 70.9% of bootstrapped models (Table 3). In the 
saturated model, the calculated C-statistic was 0.595. However, after correction for optimism, the 
C-statistic in the final model was 0.549 (Table 3).  
The Year-1 saturated prognostic model of PTS included 16 predictor variables (Table 4). 
After validation, the final model included injury severity, SDH, contusion load, craniotomy, 
craniectomy, pre-injury condition limiting physical activity, mental health treatment/psychiatric 
hospitalization, and incarceration. The model failed to converge in 10 bootstrap samples. 
Craniectomy was the most statistically significant predictor (p<0.001) and was selected in 99.9% 
of bootstrap samples (Table 4, Figure 1). Intraparenchymal fragment and seizure during acute 
care hospitalization were the last variables removed from the prognostic model during backward 
elimination, prior to determination of the final model (data not shown). The calculated C-statistic 
for the Year-1 saturated model was 0.797, which was reduced to 0.756 after adjustment for 
optimism (Table 4) 
The Year-2 saturated model included 14 predictor variables (Table 5). For Year-2, 
contusion load was collapsed into 0, 1, 2, 3, or 4 or more regions due to low sample size when 4 
and 5 or more regions were separate. Similarly, mental health disorder and/or psychiatric 
hospitalization were collapsed into three levels (hospitalization no mental health disorder [n=2], 
combined with mental health disorder and hospitalization). Following bootstrapping with 
backward elimination, SDH, intraparenchymal fragment, craniectomy, seizure during acute 
hospitalization, and pre-injury condition limiting physical activity were significant predictors. 
With the exception of seizure during acute hospitalization, each predictor was indicative of at 
≥3X greater odds of PTS at Year-2 versus those without the predictor (Table 5). Similar to Year-
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1, craniectomy was the most statistically significant predictor of PTS at Year-2 and was selected 
in 90.4% of bootstrap samples. Craniotomy was not included in model generation based on 
bivariate results (p>0.20). The C-statistic for the saturated model was 0.785, which decreased to 
0.724 after correction for optimism (Table 5).  
5.5 DISCUSSION 
We developed prognostic models of PTS during acute hospitalization, Year-1, and Year-2 
following TBI for individuals requiring hospitalization and inpatient rehabilitation at designated 
TBIMS centers. We internally validated these models using resampling techniques and generated 
discrimination statistics. Within each model, multiple risk factors were significant predictors of 
PTS at each time-point. C-statistics demonstrated that models had fair to good ability to 
discriminate between individuals with and without PTS at Year-1 and Year-2. However, the 
prognostic model for acute hospitalization did not perform much better than chance for 
predicting those who had PTS. Nonetheless, variables identified as PTS predictors over time may 
shed light on vulnerable risk groups and the temporal nature of specific clinical and demographic 
PTS risk factors. 
Sex was the only significant demographic PTS predictor (men at increased risk) and only 
in the acute care model. This finding must be interpreted with caution because of the model’s 
poor discrimination ability and data showing that sex was included in less than half (45.5%) of 
the bootstrap models, indicating sex is not a reliable predictor of acute PTS. Two large late PTS 
studies reported increased seizure risk in men, but differences were non-significant 47; 69. 
Previous early PTS studies have not examined extensively demographic characteristics as risk 
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factors other than finding young children at increased risk for early seizure versus adults 48; 66. 
We identified pre-injury limitation in learning, remembering, or concentrating as a significant 
PTS predictor during acute hospitalization. This variable was included in less than half (48.9%) 
of bootstrap samples. However, pre-injury limitation in learning may capture latent premorbid 
neurobiological differences that increase seizure susceptibility, as evidenced by increased 
epilepsy rates among individuals with developmental disabilities 137.  
Pre-injury mental health treatment and/or psychiatric hospitalization was a significant 
PTS predictor during acute hospitalization and Year-1. Previous work suggests depression 
history, prevalent in 21% of the study population, is associated with increased late PTS risk 69. 
Notably in our analyses, 22% of individuals reported history of mental health treatment and/or 
hospitalization for psychiatric disorder. Existing research indicates bidirectional relationships 
between psychiatric conditions (especially major depression) and epilepsy 138. These associations 
may be attributable to common neuropathological mechanisms, like regional monoaminergic 
dependent derangements in glutamate management and neurotransmission 138. Additionally, 
medications for mental health disorders like antipsychotics (e.g. chlorprothixene, clozapine) and 
specific antidepressants (e.g. maprotiline, venlafaxine), can decrease seizure threshold, further 
increasing seizure risk after TBI 139. Importantly, post-injury depression occurs commonly after 
TBI 140. Many individuals take anti-depressants to address clinical symptoms. Therefore, 
clinicians may need to weigh seizure risk into their selection of antidepressants in this 
population. The findings also suggest further studies to evaluate the combined seizure risk 
among individuals receiving psychotropic medications after TBI. 
Pre-injury condition limiting physical activity was a significant PTS predictor at Year-1 
and Year-2. This variable may include individuals with conditions attributable to central nervous 
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system (CNS) pathology that limit activity and could increase seizure susceptibility independent 
of TBI [e.g. cerebral palsy 141]. This variable may also include those with pre-morbid epilepsy if 
the condition impacts (or the individual perceives it impacts) physical activity (e.g. if seizures are 
not well controlled). Generally, PTS studies exclude individuals with pre-morbid seizure 
disorders due to inability to distinguish PTS from seizures due to non-traumatic etiology. The 
TBIMS does not collect information on premorbid seizure/epilepsy. However, individuals with 
premorbid seizure/epilepsy may be at risk for increased seizure frequency and/or severity post-
TBI. Future work should evaluate the impact of TBI on changes in seizure frequency/severity 
among those with pre-existing epilepsy.  
Pre-injury incarceration was a significant PTS predictor at Year-1. One study reports 
higher percentages of prior arrest and incarceration among individuals with late PTS versus those 
without late PTS 142. Incarceration is associated with increased impulsivity 143 and associated 
behaviors (e.g. aggression, risk taking, substance use) 144. These individuals may have 
underlying neuropathologies involving limbic structures and neurotransmitter disruption in the 
nucleus accumbens that impact cortical cognitive control 144, predisposing them to risky 
behaviors that may result in TBI and PTS. Incarceration may also be associated with 
developmental disability and history of violence, including previous TBI. However, these 
variables were already accounted for in prognostic modeling. Thus, incarceration may represent 
latent neurobiological traits not otherwise accounted for by data collected.  
Contrary to expectation, previous moderate/severe TBI did not predict PTS. To our 
knowledge, no previous study has examined the risk of incident PTS after multiple 
moderate/severe TBI. We hypothesized pathology from prior injury increases PTS risk after 
subsequent injury. However, the lack of significant findings may be related to low event rates, 
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with less than 3.5% of the population reporting prior moderate/severe TBI. Future work should 
investigate how multiple TBI affects biosusceptibility to complications like PTS. 
Intraparenchymal fragment was a significant PTS predictor at Year-2, consistent with previous 
research demonstrating higher PTS rates among those with depressed skull fracture 12; 47; 66 and 
pTBI 72. In our analyses, pTBI was very rare, but also partially defined by the intraparenchymal 
fragment variable, and was therefore not examined in prognostic models. Injury severity was a 
significant Year-1 predictor, where PTS odds were greater in those with severe versus moderate 
injury. At Year-2, PTS rates were 2 times higher for those with severe versus moderate TBI (data 
not shown), but injury severity did not reach statistical significance in multivariable modeling. 
The lack of predictive ability may be attributed to low sample size or inclusion of other variables 
associated with injury severity (i.e. intracranial pathologies, craniectomy).  
SDH was a significant predictor at Year-1 and Year-2, consistent with previous literature 
12; 47; 78. SDH was not a significant PTS predictor acutely, but the propensity for temporal glial 
scarring in SDH regions, and the fundamental role of glial scarring in epileptogenesis 40; 62, may 
explain the temporality of this finding. Contusion load is a marker of multifocal injury 
throughout the brain, and contusion has been identified previously as a risk factor for PTS 12; 47; 
78.  As contusion load increases, neuronal injury and apoptosis likely increase, disrupting 
neuronal circuits and predisposing focal areas to ictal discharges. Vascular damage after TBI 
leads to regional blood extravasation and subsequent generation of blood breakdown products 
within CNS tissues, perpetuating oxidative stress, another mechanism of epileptogenesis 18; 31.  
Seizure during acute hospitalization was the last variable removed from the Year-1 PTS 
model and was a significant PTS predictor at Year-2. Although there is debate regarding the 
“seizure begets seizure” construct 145, research consistently demonstrates early seizure is 
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associated with increased risk of late PTS 47; 66; 69; 70. Immediate/early seizures are considered 
provoked and non-epileptogenic. However, provoked seizures may exacerbate secondary injury 
cascades affecting neurochemical and synaptic regulation 146. Seizures cause reactive 
astrocytosis and altered glutamate management, further promoting TBI-induced excitoxicity 62. 
Reactive astrocytosis also perpetuates the injury-induced inflammatory response, propagating an 
inflammation/excitation cycle that may result in subsequent seizures 62. Thus, early seizures, and 
associated disruptions in critical neuroregulatory mechanisms after injury, may alter neuronal 
homeostasis, further causing maladaptive neuronal circuit reorganization (plasticity) in what are 
already seizure-prone systems 147. While the acute hospitalization period for the TBIMS 
population often extends beyond the first week post-TBI, the finding that these seizures 
contribute to longer term PTE risk underscores the critical need for effective PTS prophylaxis 
and revisiting whether or not current guidelines for medications and treatment duration are 
preventing immediate/early PTS effectively and reducing PTE risk 8. 
Craniotomy and craniectomy are common procedures following severe TBI. Recently, 
decompressive craniectomy (DC) has become a widely used procedure for management of 
intractable intracranial pressure. Cranial surgeries were among the strongest and most 
statistically significant PTS predictors in our models, confirming previously published findings 
47; 78. However, cranial surgery type reaching statistical significance within models varied across 
time. We hypothesize this association may stem from both anatomic and physiologic changes 
from the craniectomy and associated cranioplasty as well as late surgical complications.   
Craniotomy and craniectomy are implicated as risk factors for seizure, even when used to 
address non-traumatic CNS pathologies 89. Craniectomy carries increased risk for additional 
brain tissue damage during surgery and secondary to post-operative hematoma and edema 148. 
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Chronic complications (>1month post-surgery) can occur post-craniectomy, including poor 
wound healing, infection, and hydrocephalus 148. Complications and increased morbidity can also 
occur secondary to subsequent duraplasty/cranioplasty 149. Thus, delayed pathological 
mechanisms associated with chronic complications and subsequent cranioplasty may explain the 
temporality of craniectomy as a significant PTS predictor. Observational and retrospective 
studies note more severe injury among individuals undergoing craniectomy versus craniotomy or 
standard care 150. Our prognostic models include multiple injury severity and pathology 
measures, yet craniectomy remained among the strongest predictors, supporting the idea that 
craniectomy is associated with increased PTS risk, independent of injury severity. PTS 
prophylaxis guidelines 8, do not reflect new pharmacological agents or trends in neurosurgical 
intervention for treatment of TBI, yet may benefit from additional research that considers these 
issues.  
Although these models elucidate potentially important PTS predictors, there are 
limitations to consider. Relative to prognostic studies in general, sample sizes in current analyses 
were small. Ability to discriminate PTS was poor during acute hospitalization. Low acute model 
performance may be due to the fact that seizure status during acute hospitalization does not 
differentiate between immediate, early, and late seizures. Differentiating between these time 
points as outcomes could improve individual model performance as PTS risk factors temporally 
evolve. Alternatively, factors predicting acute seizures may be so diverse that prognostic models 
would not be effective. Acute seizures may include those detected via electroencephalogram 
(EEG). However, we do not know if EEG was used to capture seizure activity, if specific 
individuals only were monitored using continuous EEG, or if EEG monitoring/screening 
practices differed across TBIMS centers. Misclassification of PTS status from ICD-9 codes, and 
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inability to determine premorbid seizure/epilepsy disorder, also limit model performance. 
 Importantly, PTS status misclassification at Year-1 and Year-2 may also have occurred 
because PTS determination was based exclusively on self-report. Individuals who experienced 
psychogenic may have reported seizure activity. However, for large population-based 
epidemiological studies, it is not feasible to determine PTS status through in-depth neurological 
examine or medical history. Therefore, self-report remains the gold standard for seizure/epilepsy 
research. Lack of information on medication use prohibited investigating how psychotropics 
affect PTS risk. Therefore, we cannot determine if inclusion of mental health disorder/psychiatric 
hospitalization is predictive or if this variable represents increased PTS risk secondary to 
psychotropic medication use. We were also unable to control for AED effects on acute 
hospitalization or Year-1/Year-2 seizure risk, including differential effects of specific medication 
type. However, in a single TBIMS center, 96% of individuals with severe TBI received seizure 
prophylaxis during acute care 129. It is possible, but cannot be confirmed, that other TBIMS 
centers would have similar prophylaxis rates. Additionally, the TBIMS-ND includes only 
individuals surviving their acute injuries and receiving acute inpatient rehabilitation after 
moderate-severe TBI. Results here may not extrapolate to all individuals with moderate-severe 
TBI. Lastly, the observational design does not provide causal evidence among relationships with 
PTS outcome.  
Despite limitations, these prognostic models may have added benefit compared to prior 
models, which were not used clinically even though they were reliable in different study 
populations 46; 136. Previous models focused on calculating PTS probability or seizure recurrence 
over time 46; 135; 136, while our prognostic models reflect current trends in TBI diagnosis, 
treatment, and population characteristics, and investigate multiple risk factors identified in 
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previous PTS studies. Regardless, these models should be examined in independent study 
populations to determine discriminability and validity outside the TBIMS population. Individuals 
with characteristics identified in prognostic models as predictive of PTS represent 
subpopulations that may benefit from tailored seizure prophylaxis guidelines addressing unique 
premorbid characteristics, pathologies, and procedures. 
Further study is required to determine whether new evidence of biological risk factors for 
PTS improves the clinical utility of prognostic models. Year-1 and Year-2 models had optimism-
corrected C-statistics greater than 0.70 (0.756, 0.724, respectively). While these values indicate 
good discriminatory ability, there remains room for improvement. Of particular interest are 
genetic factors previously shown to be associated with accelerated epileptogenesis and seizure 
risk after TBI 104; 129. These studies suggest genetic variation remains a significant PTS risk 
factor after controlling for other factors including injury severity and SDH. Data regarding 
genetic variation in epileptogenic pathways could improve prognostic ability for PTS, much the 
way genetic information improved breast cancer prognostication 151.  As modern medical and 
prevention efforts for PTS move toward personalized medicine approaches, personal biology 
metrics like genetic variation and inflammation may contribute meaningfully to prognostication 
and treatment development. 
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Figure Legends 
Figure 1. Histogram depicting predictors of interest included in prognostic models of PTS during 
acute care hospitalization (blue), at Year-1 (red), and Year-2 (green) post-injury. Y-axis 
represents the percent of bootstrap models the predictor of interest was retained in after 
backward stepwise elimination. Variables without a column for a specific time-point were not 
considered as a predictor of interest for the time-point. PTA=post-traumatic amnesia; 
SDH=subdural hematoma; SAH=subarachnoid hemorrhage; EDH=epidural hematoma; 
SCI=associated spinal cord injury; MH=mental health; Psych Hosp=psychiatric hospitalization. 
 
Supplemental Figure 1. Consort like diagram depicting the flow of individuals used for 
development of prognostic models at progressive time-points within the TBIMS-ND. 
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5.6 TABLES 
Table 13. Risk Factors Selected for Consideration in Prognostic Models 
Variable Definition Method 
D
em
o-
gr
ap
hi
cs
 
Sex Biological sex 
Age Age at Injury 
Race Self-identified race SR 
Pe
rs
on
al
 a
nd
 M
ed
ic
al
 H
is
to
ry
 
Condition 
Significantly 
Limiting Physical 
Activity 
A condition that substantially limits one or more 
basic physical activities such as walking, climbing
stairs, reaching, lifting, or carrying prior to injury SR
Limitation in 
Learning, 
Remembering, 
Concentrating 
Difficulty in learning, remembering, or 
concentrating due to a physical, mental, or 
emotional condition that has been present for at 
least 6 months prior to injury 
SR 
Treatment for 
Mental Health 
Condition 
Received previous treatment for any mental health 
problems prior to injury (e.g. depression, anxiety, 
schizophrenia, and alcohol & drug abuse) 
SR 
Psychiatric 
Hospitalization 
Any psychiatric hospitalizations prior to injury SR 
Suicide Attempt Suicide attempt prior to injury SR 
Substance Use 
Problem 
Based on self-reported alcohol (drinks per week, 
binge drinker, alcohol use) and drug use prior to 
injury 
CV 
Incarceration Any penal incarcerations with conviction for felony prior to injury SR 
Military Service Any military service prior to injury SR 
In
ju
ry
 C
ha
ra
ct
er
is
tic
s 
Injury Severity 
Moderate: normal or abnormal imaging with 
30min < LOC < 24 hours, or 1day<PTA<7days, or 
GCS 9-12 
Severe: normal or abnormal imaging with -->LOC 
>24 hours, or PTA>7days, or GCS 3-8
MRR 
Post Traumatic 
Amnesia (PTA) 
Days of post-traumatic amnesia MRR 
Subdural 
Hematoma (SDH) 
Presence of extra-axial collection within subdural 
space including hematoma and hygroma MRR 
Subarachnoid 
Hemorrhage 
(SAH) 
Blood in ambient, basal, interpeduncular cisterns 
or cisterna magna, or along falx or tentorium MRR 
Intra-ventricular 
Hemorrhage (IVH) 
Blood documented within intra-ventricular space MRR
Epidural 
Hematoma (EDH) 
Presence of extra-axial collection within epidural 
space MRR 
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 Table 13 Continued.  
Contusion Load 
Calculated by summing the number of regions 
with parenchymal contusions documented in 
medical record. Regions were specified by cortical 
area or non-cortical focal contusion. A maximum 
of 6 regions were documented (frontal, temporal, 
parietal, occipital, focal non-cortical, not 
specified) 
CV 
Retained Fragment 
Intraparenchymal fragment including fractures 
displaced >2mm, excluding existing surgical clips 
or coils 
MRR 
Penetrating TBI 
Calculated via validated algorithm using imaging 
reports of retained fragment and mechanism of 
injury from medical record review. 
CV 
Associated Spinal 
Cord Injury 
Injury to neural elements of spinal cord present or 
absent MRR 
Seizure during 
Acute Care 
Hospitalization 
Inclusion of ICD-9 codes 780.39, 780.33, and 
345.0x  345.9x within first 20 ICD-9 codes 
reported during acute care hospitalization 
MRR 
Su
rg
ic
al
 
Pr
oc
ed
ur
es
 
Craniotomy 
Surgical procedure, defined as “cranium opened, 
something removed, cranium closed” MRR 
Craniectomy 
Surgical procedure, define as “cranium opened and 
left open” MRR 
Method abbreviations: MRR: medical record review; CV: calculated value; SR: self-report 
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Table 14. Demographic and Injury Characteristics at Baseline Visit 
  Acute Year 1 Year 2 
Sample Size 2160 1164 410 
Age at Injury* 45.5 
(20.3) 
44.3 (20.2) 41.8 (19.9) 
Sex  
Male 1574 
(72.9) 
868 (74.6) 310 (75.6) 
Female 586 
(27.1) 
296 (25.4) 100 (24.4) 
Race  
White 1455 
(67.6) 
791 (68.0) 295 (72.0) 
Black 329 
(15.3) 
177 (15.2) 59 (14.4) 
Other 369 
(17.1) 
196 (16.8) 56 (13.6) 
Admission  
Glasgow  
Coma Scale  
Mild 773 
(37.4) 
401 (35.5) 126 (32.0) 
Moderate 227 
(11.0) 
123 (10.9) 48 (12.2) 
Severe 687 
(33.2) 
407 (36.1) 143 (36.3) 
Intubated 381 
(18.4) 
197 (17.5) 77 (19.5) 
Unknown 92 (4.3) 36 (3.0) 16 (3.9) 
Post Traumatic 
Amnesia* 
22.3 
(22.8) 
1208 
(24.6) 
24.2 (27.2) 
Length of Acute Stay 
(Days)* 
20.6 
(19.5) 
21.7 (21.2) 22.2 (24.6) 
*mean(SD) 
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Table 15. Prognostic Model for Prediction of PTS during Acute Care Hospitalization 
Variables in Saturated 
Model 
Retained in 
Reduced Model 
Adjusted Odds 
Ratio 
P-value
Sex (ref=female) Yes 1.51 0.039 
Age No --- --- 
Injury Severity 
(ref=moderate) 
No --- --- 
Subdural Hematoma No --- --- 
Contusion Load No --- --- 
Craniotomy Yes 1.72 0.005 
Concurrent Spinal Cord Injury No --- --- 
Pre-Injury Condition Limiting 
Physical Activity 
No --- --- 
Pre-Injury Limitation in 
Learning/Remembering/ 
Concentrating 
Yes 1.68 0.033 
Pre-Injury Treatment for MH 
Condition/Psych Hosp 
(ref=Neither) 
Yes --- --- 
Treatment for MH Condition 1.34 0.187 
Both 1.66 0.095 
Psychiatric Hospitalization 5.01 0.004 
Pre-Injury Substance Use 
Problem 
No --- --- 
Fit Statistics Sample Size Seizure 
Prevalence 
C Statistic 
Saturated Model 1941 171 (8.8%) 0.595 
Reduced Model 0.593 
Optimism Corrected Reduced 
Model 
0.549 
Final Prognostic Model for PTS during Acute Care Hospitalization 
Seizure During Acute Care Hospitalization = 0.02 + 0.41*Sex + 0.54*Craniotomy + 
0.29*TreatMentalHealth + 0.51*TreatMentalHealth&PsychHosp + 1.61*PsychHosp + 
0.52*PreInjuryLimitationLearning 
*Unless noted, reference group for adjust odds ratio  is variable not present
MH: Mental Health; Psych Hosp: Psychiatric Hospitalization
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Table 16. Prognostic Model for Prediction of PTS at Year 1 
Variables in Saturated Model Retained in 
Reduced Model 
Adjusted Odds 
Ratio 
P-value
Post-Traumatic Amnesia No --- --- 
Injury Severity (ref=moderate) Yes 2.23 0.030 
Seizure during Acute Care 
Hospitalization 
No --- --- 
Subdural Hematoma Yes 1.77 0.26 
Subarachnoid Hemorrhage No --- --- 
Epidural Hematoma No --- --- 
Retained Fragment No --- --- 
Contusion Load  (ref=0)     Yes 
1 2.55 0.008 
2 3.35 0.001 
3 3.03 0.004 
4 1.44 0.447 
>=5 3.08 0.036 
Craniotomy Yes 2.58 <0.001 
Craniectomy Yes 4.49 <0.001 
Previous Moderate/Severe TBI No --- --- 
Pre-Injury Condition Limiting 
Physical Activity 
Yes 3.09 <0.001 
Pre-Injury Treatment for MH 
Condition/Psych Hosp        
(ref=Neither) 
Yes 
Treatment for MH Condition 1.70 0.060 
Both 2.87 0.009 
Psychiatric Hospitalization 4.87 0.061 
Pre-Injury Suicide Attempt No --- --- 
Pre-Injury Substance Use Problem No --- --- 
Pre-Injury Incarceration Yes 2.27 0.012 
Fit Statistics Sample Size Seizure 
Prevalence 
C Statistic 
Saturated Model 1039 107 (10.3%) 0.797 
Reduced Model 0.770 
Optimism Corrected Reduced 
Model 
0.756 
Final Prognostic Model for PTS at Year 1 
PTS at Year 1 = -0.35 + 0.80*InjurySeverity + 0.57*SDH + 0.94*ContusionLoad1 + 
1.21*ContusionLoad2 + 1.11*ContusionLoad3 + 0.37*ContusionLoad4 + 1.13*ContusionLoad5 
+ 0.95*Craniotomy + 1.50*Craniectomy + 1.13*PhysicalLimitation + 0.53*TreatMentalHealth
+ 1.05*TreatMentalHealth&PsychHosp + 1.58*PsychHosp + 0.82*Incarceration
*Unless noted, reference group for adjust odds ratio  is variable not present
MH: Mental Health; Psych Hosp: Psychiatric Hospitalization
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Table 17. Prognostic Model for Prediction of PTS at Year 2 
Variables in Saturated Model Retained in Reduced Model 
Adjusted 
Odds Ratio 
P-value
Injury Severity No --- --- 
Duration Post-Traumatic Amnesia No --- --- 
Seizure during Acute Care 
Hospitalization Yes 2.71 0.038 
Subdural Hematoma Yes 3.73 0.004 
Subarachnoid Hemorrhage No --- --- 
Retained Fragment Yes 3.03 0.049 
Contusion Load No --- --- 
Craniectomy Yes 3.34 0.002 
Previous Moderate/Severe TBI No --- --- 
Pre-Injury Condition Limiting 
Physical Activity Yes 3.67 0.022 
Pre-Injury Treatment for MH 
Condition/Psych Hosp No --- --- 
Pre-Injury Suicide Attempt No --- --- 
Pre-Injury Substance Use Problem No --- --- 
Pre-Injury Incarceration No --- --- 
Fit Statistics Sample Size Seizure Prevalence C Statistic 
Saturated Model 375 45 (12.0%) 0.785 
Reduced Model 0.763 
Optimism Corrected Reduced Model 0.724 
Final Prognostic Model for PTS at Year 2 
PTS at Year 2 = -0.44 + 1.00*SeizureDuringAcuteCare + 1.32*SDH + 1.11*Fragment + 
1.21*Craniectomy + 1.30*PhysicalLimitation 
*Unless noted, reference group for adjust odds ratio  is variable not present
MH: Mental Health; Psych Hosp: Psychiatric Hospitalization
88 
Figure 3. Histogram Depicting Variables Included in Bootstrap Samples for Prognostic 
Models 
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Figure 4. Traumatic Brain Injury Model System Prognostic Model CONSORT Figure 
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6.1 ABSTRACT 
Objective: Post-traumatic seizures (PTS) commonly occur following severe traumatic brain 
injury (sTBI). Risk factors for PTS have been identified, but variability in who develops PTS 
remains. Excitotoxicity may influence epileptogenesis following sTBI. Glutamate transporters 
manage glutamate levels and excitatory neurotransmission and have been associated with both 
epilepsy and TBI. Therefore, we aimed to determine if genetic variation in neuronal glutamate 
transporter genes is associated with accelerated epileptogenesis and increased PTS risk after 
sTBI.  
Methods: Individuals (N=253), 18-75yrs with sTBI, were assessed for genetic relationships with 
PTS. SNPs within SLC1A1 and SLC1A6 were assayed. Kaplan-Meier estimates and log-rank 
statistics were used to compare seizure rates from injury to 3yrs post-injury for SNPs by 
genotype. Hazard ratios were estimated using Cox proportional hazards regression for SNPs 
significant in Kaplan-Meier analyses adjusting for known PTS risk factors.  
Results: 32 tagging SNPs were examined (SLC1A1: n=28, SLC1A6: n=4). 49 (19.37%) subjects 
had PTS. Of these, 18 (36.7%) seized within 7days, and 31 (63.3%) seized between 8d-3yrs post-
TBI. Correcting for multiple comparisons, genotypes at SNP rs10974620 (SLC1A1) were 
significantly associated with time-to-first seizure across the full 3yr follow-up (seizure rates: 
77.1% minor allele homozygotes, 24.8% heterozygotes, 16.6% major allele homozygotes; 
p=0.001). When follow-up started on day 2, genotypes at SNP rs7858819 (SLC1A1) were 
significantly associated with PTS risk (seizure rates: 52.7% minor allele homozygotes, 11.8% 
heterozygotes, 21.1% major allele homozygotes; p=0.002). Adjusting for covariates, rs10974620 
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remained significant (p=0.017, minor allele versus major allele homozygotes HR: 3.4, 95%CI: 
1.3-9.3). rs7858819 also remained significant in adjusted models (p=0.023, minor allele versus 
major allele homozygotes HR: 3.4, 95%CI: 1.1-10.5). 
Significance: Variations within SLC1A1 are associated with risk of epileptogenesis following 
sTBI. Future studies need to confirm findings, but variation within neuronal glutamate 
transporter genes may represent a possible pharmaceutical target for PTS prevention and 
treatment.  
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6.2 INTRODUCTION 
Traumatic brain injury (TBI) represents an ever-growing public health problem. In the United 
States, over 2.5 million TBIs occur annually; of these, approximately 300,000 result in 
hospitalization or death 3. TBI is a major cause of morbidity and mortality and is increasingly 
recognized as a disease process with many associated chronic health outcomes. Those with 
severe TBI (sTBI) have significantly shorter life-spans versus demographically similar, non-TBI, 
populations 2. Recent data also show individuals with sTBI are 50 times more likely to die of 
seizure than age, sex, and racially similar populations 2.   
Post-traumatic seizures (PTS), defined as any seizure occurring after TBI, are classified 
based on time-to-first seizure relative to injury: immediate (<24hours), early (1-7days), and late 
(>7days post-injury) 41. Temporal classification cut-offs are attributed to differences in causal 
pathology and risk of seizure recurrence 18; 31. PTS incidence varies widely across adult TBI 
studies, likely due to differences in study design, population, and PTS definitions. In 
predominantly closed-head injury populations, incidence of immediate/early PTS and late PTS 
range from 1-12% and 4-19%, respectively 12; 47; 66; 69; 123.  PTS risk factors like injury severity, 
specific intracranial pathologies, and patient characteristics have been identified 12; 47; 66; 69; 123. 
Yet, a high degree of variability regarding who develops PTS remains. Evidence about factors 
affecting time-to-first seizure and the process of epileptogenesis after TBI is limited. Factors 
affecting time-to-first seizure can provide information on potential mechanisms associated with 
epileptogenesis. Previously, using time-to-event analysis, we reported variation in adenosine 
regulatory and IL-1b genes as associated with time to first PTS 102; 129. Pathological mechanisms 
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involving other secondary injury cascades, such as excitotoxicity, are likely contributors to 
epileptogenesis and may contribute to increased PTS risk chronically after injury 18.  
Glutamate is the most prominent excitatory neurotransmitter in the human brain. In 
response to the primary TBI, there is an immediate release of glutamate into the extracellular 
space and ion channel activation 58. These phenomena can lead to neuronal depolarization, 
disrupted cellular metabolism, and excitotoxic glutamate levels 31.  Excitotoxicity may lead to 
neuronal and astrocytic swelling, mitochondrial damage, cell death, and immediate/early PTS. 
Seizures can cause over-activation of excitatory amino acid receptors, inducing calcium 
dependent production of nitric oxide and reactive oxygen species and free radical damage to 
DNA and cellular membranes 18. Moreover, after experimental TBI, studies show regional 
decreases in glutamate transporter expression that is maintained chronically post-injury and is 
manipulable with levetiracetam 57. These observations suggest decreased glutamate clearance, 
and low-level excitoxicity, is an ongoing mechanism of TBI pathology and contributor to 
epileptogenesis. Antecedent immediate/early seizure activity may, along with altered glutamate 
transporter expression, perpetuate excitoxicity and cell death and contribute to epileptogenesis 6.  
Genetic variation within glutamate transporter genes may predispose individuals to 
excitotoxicity after TBI. There are five glutamate transporters in the human central nervous 
system (CNS), encoded by separate genes. Of these, the SLC1A1 and SLC1A6 genes encode the 
neuronal glutamate transporters, excitatory amino acid transporters (EAAT) 3 and 4. EAAT3/4 
contribute to, but are not the main transporters responsible for extracellular glutamate uptake in 
most brain regions. However, in brain regions where astrocyte expression is limited, neuronal 
glutamate transporters may play a more dominant role in glutamate clearance. EAAT4 
expression is limited to Purkinje cells, while EAAT3 is expressed on and within multiple neuron 
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types in various regions 152. In addition to its role in glutamate signal termination, studies suggest 
EAAT3 is vital to glutathione and GABA synthesis 35; 153; 154. Evidence of intracellular EAAT3 
localization suggests yet other functions in addition to glutamate reuptake and GABA synthesis. 
However, disruption of these functions could potentially increase seizure susceptibility through 
excitoxicity, decreased antioxidant reserves, or decreased inhibitory neurotransmission. Previous 
research demonstrates variation within SLC1A1 and SLC1A6 and augmented EAAT3/4 
expression, is associated with multiple neurological conditions including multiple sclerosis, 
schizophrenia, and epilepsy 154. Neuronal glutamate transporters associations with multiple 
neurological disorders reflects the importance of the excitatory/inhibitory balance and suggests 
multiple variants may alter function and/or expression and contribute to individual phenotypes 
and pathologies.  
Therefore, we hypothesized genetic variation in neuronal glutamate transporter genes 
SLC1A1 and SLC1A6 would be significantly associated with epileptogenesis, measured as 
differences in time-to-first seizure, following sTBI. Additionally, we hypothesized different 
variants would be associated with PTS in sub-components of a 3-year time frame.  
6.3 METHODS  
6.3.1 Study Design and Population 
Individuals were recruited to participate in a larger study assessing genetic relationships 
with TBI outcomes. Patients ages 18-75 presenting consecutively to a Level 1 trauma center with 
sTBI (Glasgow Coma Scale≤8), with positive head CT findings and requiring extra-ventricular 
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drainage catheter placement for intracranial pressure management, were screened. Patients were 
excluded if they had penetrating head injury, prolonged cardiac or respiratory arrest prior to 
admission, or legal proxy consent could not be obtained. To remove genetic effects of population 
stratification, analyses were limited to individuals listed as white by self/proxy-report (n=25 
participants excluded). Individuals with a premorbid seizure history (n=5) were also excluded 
due to inability to attribute seizure to injury or pre-existing pathology, leaving 253 individuals 
analyzed. The University of Pittsburgh Institutional Review Board approved all informed 
consent and study procedures.   
6.3.2 Critical Care Management of Severe TBI 
All patients were admitted to the neurotrauma intensive care unit and received treatment 
consistent with The Guidelines for the Management of Severe Head Injury 155. Generally, 
patients with sTBI received PTS prophylaxis for 1 week. 
6.3.3 Demographic and Injury Related Data 
Demographic and injury related data were documented at study enrollment. Intracranial 
pathology type was separated into seven categories using ICD-9 classification derived from 
radiological findings. These categories were dichotomized by injury types (present or absent) 
and were not mutually exclusive. Admission GCS was used to establish study eligibility, but the 
best GCS score during the first 24 hours after admission was used as a covariate in analyses. 
Injury severity score (ISS) is an overall body injury measure extracted from medical records, 
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with a maximum score of 75 based on survivability of injuries within and across body regions 
156. Medical records were reviewed for antiepileptic drug use during acute care.  
6.3.4 Single Nucleotide Polymorphism Selection 
Tagging single nucleotide polymorphisms (SNPs) for SLC1A1 and SLC1A6 were 
evaluated based on data available from the National Center for Biotechnology Information, 
HapMap Build 36. SNPs with minor allele frequency (MAF) ≥20% and pairwise r2 ≥80% with 
respect to other known SNPs in the genes selected to optimize the heterozygosity of the SNPs 
and to facilitate analysis of common variants among unrelated individuals. Identified SNPs 
captured variability in the genes including 1000 bases 5' upstream into the promoter region.   
6.3.5 DNA Extraction and Genotyping 
DNA was extracted from cerebrospinal fluid (CSF), collected via passive drainage, using 
Qiamp DNA extraction protocol (Qiagen) or from whole blood using a published salting out 
procedure 157. DNA samples were genotyped using iPLEX Gold SNP Assay (Sequenom). 
Double-masked genotype assignments were made for each SNP, and discrepancies were 
addressed using raw data or re-genotyping. Assays included blind duplicates for quality 
assessment. Genotypes for SNPs representing variability within SLC1A1 and SLC1A6 were 
evaluated. All SNPs were evaluated for Hardy-Weinberg Equilibrium (HWE), MAF, and LD 
(Figure 1) specific to the study population using Haploview 158.  
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6.3.6 Outcome Measure: Post-Traumatic Seizure 
Time-to-first seizure following TBI was the primary outcome of interest. PTS status was 
obtained by retrospective review of all electronic inpatient and outpatient medical records 
available from our medical center. Date of first seizure was determined by ambulance and/or 
emergency room report, inpatient progress or nursing note, EEG report, patient history, and 
discharge or transfer summaries. Medical record notation referring to convulsions, seizures, 
status epilepticus, or seizure disorder was considered evidence of seizure occurrence. Date of 
death was also extracted from medical records or from social security death data 
(http://www.ssa.gov/sitemap.htm). All participants were followed until date of first seizure or 
date of death. Follow-up was censored at 3 years post-injury. 
6.3.7 Statistical Analysis 
Analyses were completed using SAS-9.4 (Carry NC) and R-3.0.3.  All genotyped 
participants meeting eligibility criteria were included in analyses. Demographic and injury 
characteristics were compared between individuals who did not seize and those who seized at 
different time-points post-injury, using chi-square and Kruskal Wallis tests as appropriate. 
Individuals who seized were separated into groups based on time of first seizure (i.e. immediate, 
early, late). Due to small sample sizes, immediate and early groups were collapsed for 
comparison of demographic and injury characteristics.  
Among individuals who seized, Chi-square analyses were conducted, using Fisher’s exact 
test when appropriate, to determine if genotype frequencies differed by time of first seizure (i.e. 
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immediate, early, late). Immediate and early seizures were again combined due to small sample 
size and compared to late seizure.  
Time-to-event analyses were used to address the primary hypothesis regarding genetic 
variation and epileptogenesis after TBI over a 3-year time period. Due to linkage disequilibrium 
(LD), i.e. correlation among selected SNPs, the effective number of tests conducted was smaller 
than the number of SNPs screened. The minimum number of effective tests (Meff) was calculated 
using methods based on eigenvalues159; 160. The Meff was calculated for SLC1A1 and SLC1A6 
independently, and results were summed. A Bonferroni correction was then applied to the 
original α=0.05 using the total Meff as the number of independent tests for subsequent time-to-
event analyses. SNPs that were statistically significant after multiple comparison correction were 
further evaluated using Cox regression. 
Kaplan-Meier curves were used to estimate seizure rates at three years post-injury, 
considering the full follow-up period (i.e. time of injury through 3 years post-TBI), for individual 
SNPs by genotype, and rates were compared using the log-rank statistic. Cox proportional 
hazards regression was used to estimate hazard ratios (HR) for SNP genotypes that demonstrated 
significantly different Kaplan-Meier estimated rates of PTS based on Bonferroni corrected p-
values derived from log-rank statistics. Cox regression models were then adjusted for 
demographic and injury characteristics that differed significantly across seizure groups (no 
seizure, immediate/early, late seizure). Proportionality assumptions were examined for all 
variables. All time-to-event analyses were repeated 1) where immediate seizures were removed 
by beginning the follow-up period day 2 post-injury (individuals seizing or expiring before day 2 
excluded) and 2) where both early and immediate seizures were removed by beginning the 
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follow-up period on day 8 post-injury (individuals seizing or expiring before day 8 excluded), to 
specifically examine late PTS.  
For each follow-up timeframe, a gene risk score (GRS) was created using all SNPs that 
were nominally significant (p<0.05) in Kaplan-Meier analyses in order to explore possible 
additive effects of having multiple risk genotypes. The number of SNPs for which an individual 
was homozygous for the minor allele (risk genotype for all SNPs based on Kaplan-Meier results) 
was summed. The subsequent GRSs were then analyzed for associations with time-to-first 
seizure in their respective follow-up period.  
6.4 RESULTS 
We identified and genotyped 32 SNPs from SLC1A1 and 4 SNPs from SLC1A6. Four SNPs on 
SLC1A1 failed to genotype for >20% of the total population and were excluded. All other SNPs 
were in HWE. Therefore, we examined a total of 28 SNPs from SLC1A1 and 4 from SLC1A6 
(Supplemental Table 1). Meff calculations indicated a total of 16 independent tests (14 and 2 for 
SLC1A1 and SCL1A6, respectively), resulting in a Bonferroni adjusted significance level of 
0.003.  
Two hundred fifty-three individuals met all inclusion criteria and were genotyped. 
Similar to other studies of severe TBI, our study population was predominantly male (79.5%), 
average 35.3 years old. The majority of individuals had severe TBI as determined by best in 24hr 
GCS score (91.7%); the average best in 24hr GCS score for the total cohort was 6 (Table 1).   
Overall, 49 individuals (19.4%) developed PTS. Of these, 12 (24.5%) seized within 24 
hours, 6 (12.2%) seized within the first 7 days, and 31 (63.3%) seized between 8d-3yrs post-
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injury. Depressed skull fracture and subdural hematoma (SDH) occurred more frequently in 
individuals who seized compared to those who did not seize (Table 1). Among individuals who 
seized, there were no differences in genotype frequencies between individuals seizing 
immediately and early versus those seizing late (data not shown).  
SDH and depressed skull fracture frequencies differed significantly by seizure status. 
Therefore, we adjusted for these factors in all Cox regression models. SDH was included as a 
covariate. Since depressed skull fracture did not meet proportionality assumptions, models were 
stratified by presence/absence of depressed skull fracture. All SNPs met the assumption of 
proportionality.  
6.4.1 Time-to-Event Across Full Follow-up Period 
We found significant differences in seizure rates by genotype for rs10974620 (p=0.001), 
located on SLC1A1, when assessing the full follow-up period (Table 2). 24.8% of major allele 
homozygous (CC), 16.6% of heterozygous, and 77.1% of minor allele homozygous (GG) 
individuals seized during follow-up. Among those who seized, the average time-to-first seizure 
was twice that for heterozygous and major allele homozygous individuals versus minor allele 
homozygotes (786, 794, 384 days, respectively). Three additional SNPs in SLC1A1 (rs10815020, 
rs7858819, and rs301430) were nominally associated with differences in seizure rates. For each 
SNP, minor allele homozygotes had the highest risk of seizures 3yrs post-injury and the shortest 
time-to-first seizure (Figure 2).  
In both unadjusted and multivariable adjusted Cox regression (adjusting for covariates 
noted above) we found significant differences in seizure risk by SNP rs10974620 genotypes 
(p=0.004 and p=0.017, respectively). Individuals homozygous for the minor allele had a 
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significantly higher hazard of seizure (unadjusted HR=4.08; adjusted HR=3.43) versus major 
allele homozygotes (Table 3). There was no significant difference in hazards between 
heterozygotes and individuals homozygous for the major allele. In adjusted models, SDH was 
significantly associated with increased seizure risk (HR=2.36, p=0.016).   
No SNPs on SLC1A6 had significantly different time-to-first seizure based on Kaplan 
Meier analyses, and were not further included in Cox models.  
6.4.2 Time-to-Event Removing Immediate Seizures 
When follow-up began on post-injury day 2 (i.e. only early and late seizures included), 
there were significant differences in the 3-year seizure rates by genotype for SLC1A1 SNP 
rs7858819 (p=0.002). Minor allele homozygous (TT) individuals had the highest seizure rates 
(52.7%) versus heterozygotes (11.8%) and major allele homozygotes (CC; 21.1%) (Figure 3). 
Among those who seized, minor allele homozygous individuals had the shortest time-to-first 
seizure (270 days) versus major allele and heterozygotes (520 and 937 days, respectively). There 
were nominal differences by genotype for SLC1A1 SNP rs10974620 (p=0.004) (Table 2). In Cox 
regression, seizure risk for SNP rs7858819 minor allele homozygous individuals was 
significantly greater versus major allele homozygotes (HR=3.9, p=0.005). After adjusting for 
SDH and stratifying by depressed skull fracture status, the rs7858819 genotype effects were 
attenuated, but remained significantly associated with seizure risk (HR=3.39, p=0.023; Table 3). 
In the adjusted model, SDH was also significantly associated with seizure (HR=3.11, p=0.013). 
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6.4.3 Time-to-Event Examining Late Seizures Only  
To determine if there were significant associations with genotypes in epileptogenesis of 
late PTS, analysis was restricted to follow-up beginning on post-injury day 8. Associations with 
genotypes at SNPs rs10974620 (p=0.044) and rs7858819 (p=0.009) were nominally significant 
(Table 2).   
6.4.4 Gene Risk Scores 
Across the full follow-up, Kaplan-Meier estimates differed significantly for individuals 
with no risk genotypes, one, or more than one risk genotypes (3yr seizure rates: 16.7, 45.5, 
42.9%, respectively; log-rank p-value <0.001). Results were similar when a gene risk score was 
calculated for follow-up beginning on day 2. 3yr seizure rates were 12.8, 33,3, 33.3% for 
individuals with 0, 1, or more than 1 risk genotype (log-rank p-value=0.005). However, there 
were no significant differences between individuals having one risk genotype versus those with 
more than one risk genotype (data not shown).  
6.5 DISCUSSION 
Variation in genotype, and changes in neuronal glutamate transporter expression, has been 
associated with seizure and epilepsy. TBI results in decreased glutamate transporter expression 
57, potentially perpetuating ongoing excitotoxic injury and damage after TBI, as well as 
facilitating a pro-epileptogenic environment. However, it remains unclear whether genetic 
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variation in neuronal glutamate transporters affects epileptogenesis or seizure development 
following TBI. Therefore, we examined associations between SCL1A1 and SLC1A6 genetic 
variation and epileptogenesis, measured by time-to-first seizure, among individuals with severe 
TBI.  
We found genetic variation in SLC1A1, but not SLC1A6, was associated with reduced 
time-to-first seizure and increased seizure risk during a 3-year post-injury follow-up. Individuals 
homozygous (GG) for the minor allele at SNP rs10974620 had significantly higher seizure risk 
over the 3yr follow-up period, even after adjusting for relevant covariates. Individuals 
homozygous (TT) for the SLC1A1 SNP rs7858819 minor allele also had greater risk of PTS in 
multivariable models when follow-up began on day 2 post-injury (after the immediate seizure 
period). Both SNPs were nominally associated with the other time periods characterized. We 
found no significant differences in seizure risk when comparing individuals with one risk 
genotype to those with more than one risk genotype in each timeframe, suggesting no additive 
genetic effects. The high degree of LD (Figure 1) among genotypes for SNPs significantly 
associated with seizure risk within our study population, approximately 2,600bp from one 
another within the same intron, is one possible explanation for this finding. Although the sample 
size is small, possible differences in SNP associations with PTS over time may indicate that 
genetic variants within SLC1A1 influence temporally dynamic PTS risk post-injury. Future 
follow-up studies should examine this hypothesis. 
The SLC1A1 locus encodes EAAT3, is located on chromosome 9p24, and is 
approximately 97kb in length. SNPs rs10974620 and rs7858819 are both located within the 
second intron. We used the most recent Genome Reference Consortium data, GRCh38, from 
Utah residents with northern/western European ancestry (CEPH; 
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http://hapmap.ncbi.nlm.nih.gov/citinghapmap.html.en) to explore gene regions around 
rs10974620 and rs7858819. In the CEPH population, little information regarding LD for 
rs10974620 is available. However, rs7858819 may be tagging a region that contains multiple 
functional variants as it is in LD with a 13.5kbp region extending from intron two into intron five 
that includes multiple missense polymorphisms. 
EAAT3 terminates post-synaptic action and maintains physiological levels of glutamate. 
However, EAAT3 is not as critical for terminating glutamate signaling when compared to glial 
glutamate transporters (EAAT1/EAAT2) 161. EAAT3’s binding affinity and synaptic location 
suggests it may have a more prominent role in glutamate signal termination in pathological 
conditions involving elevated extracellular glutamate levels 59. EAAT3 also facilitates cysteine 
transport 162, and thus, cysteine dependent glutathione (antioxidant) production 35. EAAT3 is 
highly expressed on glutamatergic and GABAergic neurons 152 in the cortex, hippocampus, 
cerebellum, and basal ganglia 163. Regional expression suggests EAAT3 mediated glutamate 
transport supplies GABAergic neurons with intracellular glutamate required for GABA 
production. Using a similar cohort, our laboratory previously reported variation in the gene 
encoding glutamic acid decarboxylase (GAD1), responsible for synthesizing GABA from 
glutamate, is also associated with increased late PTS risk 104. Therefore, disruption in EAAT3 
function and/or expression may reduce antioxidant reserves and impair GABA production, 
subsequently increasing excitatory tone and contributing to epileptogenesis.  
Animal models examining EAAC1 (EAAT3 rodent analog) in epilepsy and seizure 
induction show EAAC1 antisense treatment reduces EAAC1 availability and increases epilepsy 
development in a dose dependent manner 164. In a similar antisense treatment model, functional 
EAAC1 loss was associated with proportional increases in epileptiform activity and EEG 
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abnormalities 153. The same study showed greater excitability in EAAC1 anti-sense treated 
animals, and decreased GABA levels in EAAC1 antisense treated animals versus controls 153. 
Other experimental models involving chemically induced epilepsy demonstrate significantly 
increased EAAC1 levels compared to controls 165, suggesting increased EAAC1 expression is 
needed to manage elevated glutamate levels associated with seizure. Kainic acid induced 
epilepsy models also show EAAC1 can translocate from the membrane to the intracellular space 
during early epileptic activity 166. Another study using pentylenetetrazol kindling showed 
increased EAAC1 expression 24 hours after seizure, but animals with lower EAAC1 levels were 
more easily induced into an epileptic state 167. Taken together, low EAAC1 expression increases 
seizure susceptibility, and changes in EAAC1 expression or location within the epileptic brain 
may compensate for or contribute to glutamatergic mechanisms of epileptogenesis.  
EAAT3 expression studies in humans are few, but they report individuals with temporal 
lobe epilepsy (TLE) having altered neuronal EAAT3 mRNA compared to controls 165; 168. 
Studies report differences in EAAT3 immunoreactivity linked to the presence of hippocampal 
sclerosis, with increased EAAT3 immunoreactivity occurring on granule cells from sclerotic 
regions 168. Conversely, among individuals with pharmacoresistent neocortical epilepsy, EAAT3 
expression was decreased in epileptic regions compared to non-epileptic tissues from the same 
individuals 169.   
Multiple candidate gene studies have reported SLC1A1 genetic variation with psychiatric 
conditions including post-traumatic stress disorder 170, autism spectrum disorder 171, and 
schizophrenia 154. The most data regarding human SLC1A1 genetic variation and psychiatric 
disorders is reported with obsessive-compulsive disorder (OCD). Both family based linkage 
studies and case-control association studies of unrelated individuals have reported SLC1A1 
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variation is associated with OCD diagnosis and age of onset 172; 173. SLC1A1 haplotypes 
associated with OCD have been reported and include SNPs examined within our current analysis 
172; 173, but SNPs included and risk allele designations differ across studies. One study reported 
that a three SNP haplotype, including rs301430 and rs7858819 C-alleles, was significantly 
associated with OCD 173. These investigators also examined mRNA levels of SLC1A1 from brain 
tissue of individuals with bipolar and schizophrenic disorders and healthy individuals. They 
reported that an increasing the number of minor alleles for rs301430 and rs7858819 was 
associated with increased mRNA levels 173. Overall, these studies, while not drawing consistent 
conclusions regarding risk alleles, provide evidence that genetic variation within specific regions 
of SLC1A1 is associated with pathological phenotypes. Further investigation is required to 
identify potentially functional variants and establish how they may be associated with 
phenotypes under investigation. Similarly, our study suggests further work is needed to evaluate 
potentially functional SNPs in regions tagged by rs7858819 and rs10974620 and their potential 
association with PTS. 
In addition to activity-related expression changes, EAAT3/EAAC1 expression and 
trafficking can be modified via post-translational mechanisms and interaction with multiple 
kinases 154, potentially affecting glycosylation and phosphorylation sites important for 
transporter function and post-translation regulation 152. EAAT3 also interacts with intracellular 
proteins for proper anchoring on cell membrane and EAAT3 trafficking 154. Specific alleles may 
result in changes to amino acid residues or protein misfolding, disrupting these interactions and 
affecting membrane protein expression.  
Additional studies are needed to examine differences in SLC1A1 expression among 
individuals with TBI who do and do not develop PTS. Further research regarding how specific 
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genetic variation may effect translation, expression, and/or trafficking of EAAT3 is essential to 
assess whether pharmacological modulation may mitigate or prevent PTS. Specifically, animal 
TBI models that lead to post-traumatic seizure may also provide specific opportunities to 
investigate, not only glutamate concentration and reduced EAAC1 expression after TBI, but also 
if levetiracetam associated increases in post-TBI glutamate transporter expression 57 translate at 
all to reduced PTE. Additionally, EAAT3’s function differs across neuro-developmental phases. 
Thus, effects of SLC1A1 genetic variation on PTE may vary across the age spectrum of those 
sustaining TBI. Also, TBI-induced EAAT3 disruption may interact with genetic variation to 
impact neuroplasticity during the post-injury period. In addition to examining the role of 
neuronal glutamate transporters, future work should assess whether glial transporters are 
independently associated with epileptogenesis post-TBI and how these transporters may work 
collectively with other candidate gene variants to affect excitatory and inhibitory pathways 
influencing PTS.  
Our results represent novel insights regarding the relationship between genetic SLC1A1 
variation and PTS risk. However, our results are limited by small sample size and low event 
rates. Although we did not find statistically significant relationships between SNPs and late PTS 
risk, it is possible there was not sufficient power to detect differences. Time-to-first seizure was 
classified based on an intensive medical record review of individuals cared for through the 
largest health care provider in the geographic region. However, seizure status and time-to-first 
seizure may have been misclassified due to missing data on healthcare provided outside of this 
system. To minimize differences in allelic frequency by race and ancestry, we limited our 
analyses to individuals self-reporting race as white, however, residual population stratification 
may still remain. Furthermore, our results cannot be generalized to other non-European ancestry 
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populations. We also included only individuals with severe TBI, and our results may not 
generalize to less severe TBI populations. Critically, additional studies are needed to replicate 
our findings in similar populations and also assess associations with functional SNPs within the 
LD block implicated in our study. Increasing our knowledge of genetic variants affecting PTS 
development may improve prognostic seizure models (In Review), possibly enabling researchers 
and clinicians to assess more accurately the probability of individual PTS development. If 
validated, these results may represent an innate factor by which to identify individuals with 
increased PTS risk; also EAAT3 may be a potential therapeutic target for PTS prevention and 
treatment. 
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Figure Legends 
Figure 1. Haploview generated gene map displaying linkage disequilibrium (D’) for SNPs 
located on SLC1A1 (panel A) and SLC1A6 (panel C). Deeper red colors are indicative of greater 
D’ values. Panel B shows a magnified view of SNPs on SLC1A1 shown to be associated with 
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time to first seizure in the current analyses (19=rs10974620, 20=rs10815020, 21=rs7858819, 
24=rs301430). 
 
Figure 2. Kaplan Meier estimates for time to first seizure by SLC1A1 SNP rs10974620 genotypes 
for full follow-up (Time of Injury to Three Years). 
 
Figure 3. Kaplan Meier estimates for time to first Seizure by SLC1A1 SNP rs7858819 genotypes 
for follow-up beginning day 2 post-injury to three years (individuals seizing or expiring before 
day 2 excluded). 
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6.6 TABLES 
Table 18. Population and Injury Characteristics by Seizure Status 
 No Seizure Immediate/Early Seizure Late Seizure P value* 
Sample Size 204 (80.6) 18 (7.1) 31 (12.3) --- 
Age at Injury, mean 
(SD) 35.40 (15.71) 37.17 (16.57) 33.65 (13.47) 0.825 
Sex, males 163 (79.9) 14 (77.8) 24 (77.4) 0.935 
Admission GCS        0.543 
Severe (3-8) 187 (91.7) 17 (94.4) 28 (90.3)   
Moderate (9-12) 16 (7.8) 1 (5.6) 2 (6.5)   
Mild (13-15) 1 (0.5) 0 (0) 1 (3.2)   
ISS, mean (SD) 35.87 (9.69) 34.94 (8.21) 31.7 (7.8) 0.057 
Received Acute 
Seizure Prophylaxis 192 (94.1) 18 (100) 31 (100) 0.422 
Depressed Skull 
Fracture 28 (13.7) 3 (16.7) 10 (32.3) 0.039 
Subdural Hematoma  119 (58.3) 13 (72.2) 26 (83.9) 0.013 
Subarachnoid 
Hemorrhage 140 (68.6) 12 (66.7) 20 (64.5) 0.874 
Diffuse Axonal Injury 65 (31.9) 5 (27.8) 8 (25.8) 0.814 
Epidural Hemorrhage 27 (13.2) 4 (22.2) 7 (22.6) 0.226 
Contusion 101 (49.5) 8 (44.4) 14 (45.2) 0.863 
Intraventricular 
Hemorrhage 66 (32.4) 5 (27.8) 8 (25.8) 0.788 
Intracerebral 
Hemorrhage 73 (35.8) 7 (38.9) 10 (32.3) 0.880 
* p-value for chi-square and Kruskal-Wallis tests comparing 3 groups 
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Table 19. SNPs in SLC1A1 with Significantly Different Seizure Rates Determined by 
Comparison of Kaplan Meier Curves using Log Rank Statistic 
 
 Full Follow-Up No Immediate 
Events 
No Immediate or 
Early Events 
 3Yr 
Seizure 
Rate (%) 
P-value 3Yr 
Seizure 
Rate % 
P-value 3Yr 
Seizure 
Rate % 
P-value 
rs10974620  0.001  0.004  0.044 
CC 24.8  20.3  19.7  
GC 16.6  12.0  10.7  
GG 77.1  71.4  66.7  
rs10815020  0.007  0.050  0.134 
AA 25.8  22.6  21.9  
AG 21.1  14.9  13.8  
GG 58.4  48.0  42.9  
rs7858819  0.035  0.002  0.009 
CC 23.7  21.1  20.5  
CT 21.2  11.8  10.6  
TT 56.4  52.7  47.5  
rs301430  0.033  0.018  0.072 
TT 25.8  22.1  20.7  
CT 18.9  12.3  12.3  
CC 49.3  42.5  38.1  
All genotypes in order of major allele homozygous, heterozygous, minor 
allele homozygous 
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Table 20. Results from Unadjusted and Adjusted Cox Proportional Hazards Regression 
Models for Two SNPs in SLC1A1 
Model Hazard Ratio 95% Confidence 
Interval 
P-Value 
Unadjusted Models 
rs10974620 
      Ref = CC   0.004 
CG 0.67 0.34 – 1.34  
GG 4.08 1.58 – 10.55  
rs7858819 
      Ref = CC   0.005 
CT 0.51 0.22 – 1.18  
TT 3.90 1.35 – 11.31  
Adjusted Models* 
rs10974620 
      Ref = CC   0.017 
CG 0.68 0.34 – 1.35  
GG 3.43 1.26 – 9.34  
rs7858819 
      Ref = CC   0.023 
CT 0.56 0.24 – 1.32  
TT 3.39 1.10 – 10.46  
rs10974620 from full follow-up model;  
rs7858819 from model beginning day 2 post-injury 
*Adjusted for subdural hematoma, stratified by depressed skull 
fracture 
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Table 21. Supplemental Table: Allele Frequency and Location Information for SNPs 
Examined in Time to First Seizure Analyses 
Gene SNP 
Base 
Pair 
Position 
Minor 
Allele 
Frequency Alleles 
SCL1A1     
 RS7045401 4493526 0.34 T:G 
 RS10814991 4495254 0.43 C:T 
 RS10814993 4497428 0.33 A:C 
 RS10739062 4502848 0.45 C:G 
 RS10491732 4506655 0.35 C:T 
 RS7030825 4509735 0.32 C:T 
 RS7041093 4512200 0.25 T:C 
 RS12342908 4516255 0.29 G:A 
 RS17755777 4516768 0.29 T:C 
 RS10815002 4524549 0.30 T:C 
 RS7021569 4527113 0.31 C:G 
 RS7025968 4528150 0.47 C:G 
 RS7848533 4539377 0.47 A:C 
 RS10758631 4546319 0.46 C:A 
 RS6476876 4548122 0.34 C:G 
 RS10739065 4550752 0.32 A:C 
 RS10758632 4552509 0.21 G:C 
 RS10739066 4555923 0.41 A:T 
 RS10974620 4557296 0.20 C:G 
 RS10815020 4557770 0.26 A:G 
 RS7858819 4559892 0.22 C:T 
 RS7022772 4566210 0.26 C:A 
 RS2072657 4576451 0.29 T:G 
 RS301430 4576680 0.27 T:C 
 RS301979 4576851 0.29 C:G 
 RS6476879 4577346 0.41 C:A 
 RS301434 4582082 0.46 G:A 
 RS3087879 4586808 0.35 G:C 
SCL1A6     
 RS10414225 15062223 0.36 G:T 
 RS873599 15068860 0.30 T:A 
 RS10403281 15080117 0.28 G:C 
 RS3746295 15083693 0.43 A:C 
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Figure 5. Linkage Disequilibrium Maps for SLC1A1 and SLC1A6 
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Figure 6. Seizure Curves for rs10974620 During Full Follow-up 
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Figure 7. Seizure Curves for rs7858819, Follow-up Beginning Day 2 
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7.0  GENERAL DISCUSSION 
7.1 SUMMARY 
In the current body of work, we present relatively recent epidemiological trends and risk factors 
of PTS and developed prognostic models for PTS at different time-points post-TBI.  
 Immediate seizures are usually considered a direct response to the primary head injury, 
non-epileptic in nature, and do not influence treatment decisions in an acute setting, with the 
exception of standard seizure prophylaxis44. Yet, Manuscript One demonstrates individuals who 
developed immediate seizures have a significantly greater risk of late PTS at 1 and 5 years post-
TBI compared to individuals with no seizure activity during their acute hospitalization. 
Conversely, those with early seizure were not at greater risk. Any seizure during acute 
hospitalization was also identified as a predictor of late PTS. Although an earlier seizure is 
consistently cited as a risk factor for late seizure 12; 47; 69; 77; 78, the current analysis is one of the 
first reports to specifically delineate the impact of immediate and early seizure separately on late 
PTS. These findings support the concept that immediate seizures may themselves initiate 
pathological mechanisms that facilitate/accelerate epileptogenesis.  
 Prognostic models developed in Manuscript Two identified significant predictors, such 
as personal history and neurosurgical procedures, which could impact screening of patients with 
TBI for potential risk of late PTS and could justify research re-evaluating seizure prophylaxis 
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guidelines, particularly for those deemed at high risk. We also identified relationships between 
seizure during acute hospitalization and late PTS risk, with additional implications for the 
potential efficacy of current seizure prophylaxis guidelines.  
 Manuscript Three identified SNPs within neuronal glutamate transporter genes that are 
significantly associated with seizure risk and epileptogenesis following moderate to severe TBI. 
These findings add to existing research regarding personal biology in PTS risk and have multiple 
implications regarding future directions for PTS genetics research, stratified clinical trials, and 
novel drug discovery or repurposing for PTS that may impact practice and policy.  
7.2 IMPLICATIONS AND RECOMMENDATIONS 
Findings form the current body of work highlight existing and introduce new concepts that may 
affect future research and programmatic decisions impacting those at risk for PTS. The finding 
that immediate seizure increases late PTS risk must be further examined to determine if this 
result can be replicated. If validated in external populations, individuals with immediate seizures 
following TBI may represent a subpopulation that would benefit from increased and/or 
prolonged seizure monitoring. Individuals seizing immediately post-injury who receive 
prophylaxis and develop late PTS may also represent a high-risk population with genetic 
variation within pathways relevant to excitotoxic injury that could provide insight into 
epileptogenesis and biological pathways outside of the effects of AEDs. Future work should 
examine the effect of immediate seizures on late PTS risk, controlling for other known risk 
factors. Additionally, the effects of prophylactic and anti-epileptic medications on late PTS risk 
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and pathology must be examined in more detail, including temporal relationships regarding AED 
administration and attaining effective serum levels.  
 Additionally, novel prognostic markers of acute symptomatic and late PTS were 
identified. Future research to validate the models in external populations is necessary. If 
validated, the prognostic models could be used to develop clinical decision algorithms and for 
providing a much-needed tool to assess the probability of developing PTS at an individual level, 
such as readily accessible risk assessment calculators similar to the Breast Cancer Risk 
Assessment Tool based on validated prognostic models174. These tools could enable physicians 
to more accurately discuss the risk of PTS with individual patients, encourage more frequent 
monitoring, inform and extend PTS prophylaxis periods when needed, and provide greater 
education regarding late PTS and signs and symptoms of seizure activity.  
 Future research should also continue to examine personal biology, including genetic 
variation, as risk factors for PTS. Incorporating genetic risk into our current prognostic models 
may account for (at least some) risk variation attributable to personal biology and may help 
improve the model’s reliability and provide even more accurate probability estimates. 
Ultimately, accurately screening individuals with moderate to severe TBI, and stratifying these 
individuals by PTS risk, could facilitate future research and improve care. Identifying individuals 
with immediate seizures who received prophylaxis yet developed late PTS, and genetic risk 
factors could provide information regarding potential mechanisms of epileptogenesis. This 
information may then lead to reverse-translational (i.e. from bedside to bench) research for the 
development of novel pharmaceutical treatments. Future clinical trials to investigate the 
effectiveness of tiered prophylaxis regimens could also benefit from the ability to identify 
subpopulations at high risk of PTS. Based on the body of work, and the potential impact on 
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future research, the recommendation to re-investigate the current PTS prophylaxis guidelines 
should be made. Updated guidelines may be particularly beneficial for individuals with 
immediate seizures and those undergoing neurosurgical procedures, particularly craniectomy.  
7.2.1 Traumatic Brain Injury Model Systems (TBIMS) 
The findings from Manuscripts One and Two, examining incidence and prognostic models for 
PTS, directly address future implications for the TBIMS and its potential impact on TBI 
survivors with PTE. As one of the longest running, federally funded prospective observational 
studies of recovery and outcomes following moderate to severe TBI, TBIMS research efforts are 
vital to our understanding of the natural history of TBI, and its complications and recovery 
course, including PTS. However, many lessons, including the importance of assessing the impact 
of changes to data collection, can be learned and recommendations made from the current work.  
 Primarily, there are major limitations for longitudinal research when variables are 
dropped, added, or changed throughout the course of the study. For example, due to changes in 
variables collecting seizure information at baseline and during follow-up interviews, we were 
unable to leverage for our analysis the full number (over 13,000) of individuals enrolled and 
followed in the TBIMS-NDB. Instead, changes to seizure variables resulted in two mutually 
exclusive cohorts, one with data differentiating time of seizure during acute hospitalization and 
one without. Therefore, we could not examine immediate, early, and late seizure during acute 
care as separate risk factors for the majority of individuals in the dataset, limiting statistical 
power. It is understood that as research outside the TBIMS progresses, novel risk factors or 
outcomes may be identified and variables added. Dropping or changing variable definitions is 
detrimental to ongoing research efforts. However, adding a substantial number of variables to a 
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longitudinal study could strain available resources and add to participant burden. Therefore, 
researchers must assess planned changes and dropping or revising variables to determine the 
future effect of research efforts involving the variables in question. Prospective longitudinal 
studies should clearly define variables of interest prior to study initiation and continue to collect 
variables important to the study’s specific aims and objectives throughout study duration. For 
studies such as the TBIMS, which has been continuously funded for 27 years and may continue 
to be funded well into the future, there are likely additional stakeholders to consider when 
revising data collection. Such stakeholders may potentially include the funding agency and 
associated Knowledge Translation Centers, as well as the larger TBI research community. 
 The TBIMS research efforts focus primarily on psychosocial and behavioral outcomes. 
However, the TBIMS provides an excellent infrastructure for collecting and analyzing data 
regarding clinical complications and long-term sequelae of TBI, including PTS. Additional 
variables regarding clinical endpoints, especially those pertinent to PTS (e.g. AED use), should 
be considered for inclusion in data collection procedures. Similarly, the TBIMS research efforts 
would likely benefit from the inclusion of additional clinical variables pertaining to acute care as 
well as premorbid condition variables, particularly premorbid history of epilepsy. Including 
previous history of epilepsy would allow investigation of the effects of TBI on seizure frequency 
and severity.   
 In the future, Model Systems investigators, as well as outside investigators, should 
capitalize on the existing infrastructure, as well as researcher experience and expertise, for 
collecting medication and biological data (e.g. blood draw for biomarker and genetics). 
Medication data during acute hospitalization and throughout study participation would allow 
researchers to examine the effect of medication treatments on outcomes. Information pertaining 
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to AED use (acute and chronically) would allow comparison of late PTS incidence, seizure 
frequency, comorbidities, and adverse effects between different AEDs. Including collection of 
biological specimens would allow researchers to examine individual variability in genetic 
pathways relevant to epileptogenic mechanisms to identify novel risk factors, prognostic factors, 
and possible points of intervention to prevent PTS.  
7.2.2 Federally Funded Research Efforts  
Despite multiple federal institutes and agencies funding and attempting to streamline TBI and 
epilepsy research, the capability to examine PTS and examine many of the questions raised by 
the current body of work remains low. The NINDS Common Data Elements (CDE) includes two 
case report forms (CRFs) to collect information regarding seizure activity. However, none of the 
suggested variables can delineate immediate from early seizures, nor do they capture information 
on seizure frequency. One of the CRFs focused on post-traumatic epilepsy (i.e. late PTS) 
screening does differentiate seizures occurring before and after 7 days post-injury and documents 
if AEDs are prescribed. Yet, no information regarding seizure prophylaxis, specific AED 
medications, or late seizure frequency is captured.  
 Even if future PTS research collected data specified by existing CRFs, researchers would 
still not be able to examine important questions related to PTS risk, prophylaxis, or treatment. 
Therefore, more detailed information including specific time of first seizure, frequency of 
seizures, and prophylaxis and AED use must be collected. Including immediate and early 
classification categories and details on prophylaxis within the NINDS CDEs, and providing a 
standardized CRF, may encourage researchers to collect this information. PTS CDEs could then 
be incorporated into the Federal Interagency Traumatic Brain Injury Research (FITBIR; 
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https://fitbir.nih.gov/) database and pooled across multiple studies. This infrastructure would 
enable researchers to examine immediate and early seizures, as well as the effect of prophylaxis, 
in a larger more heterogeneous sample, providing greater statistical power to examine risk 
factors for immediate verse early seizure, and immediate and early PTS as risk factors for late 
PTS.   
 Future efforts from the NIH and other federal funding sources should explore the 
possibility of establishing a biorepository in partnership with the TBIMS network. 
Biorepositories are a critical tool in translational, clinical, and epidemiological research175. Prior 
to establishment of a biorepository, it would be necessary to examine the associated costs and 
potential added value associated with a large repository. In many highly prevalent diseases, 
heavily influenced by environmental factors and less so by inherited traits, genetic information 
does not substantially add to the prediction of disease on an individual basis 176; 177. PTS, 
particularly late PTS (i.e. PTE), is likely a condition not heavily influenced by external 
environmental factors. As such, genetic predisposition may play a large part in risk estimation. 
Few studies have examined genetic risk factors for late PTS controlling for known 
environmental risk factors like repetitive head injury or post-injury alcohol and substance sue. 
Yet, studies do control for injury associated risk factors (e.g. subdural hematoma, depressed skull 
fracture, and/or injury severity) and demonstrate significant associations, between genetic 
markers and late PTS 102; 103; 129. Analyses should be completed to investigate potential 
improvement to a C-statistic, or area under the receiver operating characteristic curve, when 
genetic risk factors are added to a predictive model. The reasonably large relative effect sizes for 
genetic risk factors (hazard ratios estimated to range from 2.9 to 4.5 for various SNPs) 102; 129 in 
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prior studies increases optimism that genetic risk factors would provide sufficient added benefit 
to justify the cost of a future repository.  
 Due to the large number of sites across different regions involved in the TBIMS, and with 
different laboratory capabilities and experience, establishment of a centralized biorepository 
would be essential. Many organizations, including NINDS, have established “best practices” for 
the successful development and execution of biorepositories178. One, central biorepository for the 
TBIMS would help to eliminate multiple challenges when trying to combine information from 
biological specimens processed at multiple sites and overcome issues inherent to small, 
fragmented studies of biomarkers, particularly genetics. A centralized biorepository for the 
TBIMS, and collection of biospecimens for genetics research, would allow investigation of 
research questions critical to our understanding of PTS.  
 In addition to a TBIMS biorepository, a TBI specific biorepository at an NIH institute 
would also greatly enhance the capability of researchers to investigate genetic questions related 
to PTS. The NIH has already established biorepositories within the National Cancer Institute and 
the National Heart Lung and Blood Institute. Additionally, the National Institute on Neurological 
Disorders and Stroke funds multiple biorepositories, primarily for banking of post-mortem tissue 
in neurodegenerative research. The establishment of a central TBI biorepository overseen by a 
specific NIH institute would enable the organization to sponsor, oversee, and report on 
biospecimen collection protocols179. A central body could also oversee the use of banked 
biospecimens, which is critical to prevent misuse of samples and unnecessarily redundant 
research, and for scientific review of proposals to use banked samples to preserve quantities.  
 In addition to a central biorepository and governing body to facilitate sharing of banked 
biospecimens, a review of current data sharing policies and data repositories could facilitate 
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future PTS research. The FITBIR was recently established by the NIH and Department of 
Defense (DoD) to share TBI related data and aid collaboration between investigators. While in 
theory, a centralized data repository could enhance data sharing, there are many reservations 
from federally funded investigators regarding FITBIR’s feasibility and effective stewardship 
with managing the equitable and ethical use of the large datasets mandated for inclusion under its 
governance. FITBIR includes a committee to approve requests to use deposited data. However, it 
is not clear if requests must include research proposals previously reviewed for scientific merit, 
potentially by a federal funding agency, or by an IRB. Additionally, there is no notification 
system to inform investigators that the data they contributed is being requested for release, 
utilized or published. Therefore, as it stands, FITBIR does not foster a sense of collaboration 
among investigator or an effective roadmap for increasing the impact of TBI research datasets on 
clinical research and practice.  
7.3 PUBLIC HEALTH SIGNIFICANCE 
PTS, including PTE, pose a significant public health burden. Using TBI data from the CDC, and 
the incidence of late PTS in our cohort, of the 275,000 TBIs in the US that result in 
hospitalization annually, approximately 32,000 individuals will develop late PTS within the first 
year post-injury. An additional 24,000 individuals hospitalized for TBI will develop late PTS by 
5 years post-injury. Similarly, using this estimate in conjunction with data regarding the annual 
incidence of epilepsy180, we can calculate that incident cases of late PTS within the first year 
post-injury account for approximately 20% of the annual incidence of all epilepsy cases.  
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 The Institute of Medicine’s Committee on the Public Health Dimensions of the Epilepsies 
recognizes the role of continued prevention efforts for established epilepsy risk factors, including 
TBI, to decrease the public health burden of epilepsy180. Yet, CDC statistics indicate no decrease 
in the incidence of moderate and severe TBI, but it does document decreases in TBI resulting in 
death over the past decade. Similarly, data presented in Manuscript One demonstrate incidence 
of acute symptomatic and late PTS is slightly higher in the TBIMS cohort examined compared to 
previous PTS studies. Reasons for these modest differences are multifactorial and likely include 
more individuals surviving moderate/severe TBI and being at risk of PTS, more common use of 
EEG to monitor for seizure activity resulting in increased detection, as well as differences in 
study design. As research and modern medicine continue to advance, it is likely that survival 
after moderate to severe TBI will continue to increase. Subsequently, the number of individuals 
at risk of developing chronic complications, including PTS, will also increase.  
 Although antiepileptic drugs (AEDs) are recommended during the first seven days 
following TBI to suppress seizure activity during this time period, there is no effective 
prophylactic treatment for late PTS (i.e. PTE). Compounding this problem, individuals who 
develop seizures immediately after injury, likely prior to administration of early seizure 
prophylaxis, are at an increased risk for late PTS.  
 Prophylactic antiepileptic drug (AED) use to prevent late PTS is not recommended due to 
common multifaceted adverse effects, potential for interaction with other medications, and the 
need for recurrent healthcare visits to monitor for therapeutic levels. Many common adverse 
effects are related to AED mechanism of action and manifest as CNS signs and symptoms 
including drowsiness, dizziness, cognitive impairment, and psychiatric effects, among others181. 
Individual variability, such as premorbid and family history and genetic variance, may contribute 
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to who will develop adverse symptoms following AED administration. The impact of individual 
variability on adverse effects is likely magnified following TBI due to highly heterogeneous 
secondary injury cascades, which may affect multiple neuro-chemical processes. Future research 
is needed to examine differences in adverse drug effects among individuals with late PTS 
compared to individuals with epilepsy of non-traumatic etiology.  
 The heterogeneous nature of TBI may also be a complicating factor in treating late PTS 
once a diagnosis is made. There are no specific medications for the treatment of late PTS 
compared to epilepsies of different etiology. Late PTS is often refractory to clinical 
management182, possibly resulting in numerous dose and/or medication changes as well as 
polytherapy. Even if effective medication and dosing levels are identified, individuals with 
cognitive or behavioral deficits secondary to TBI may have difficulty adhering to complicated 
medication regimens.  
 In addition to adverse effects of AED treatment, psychiatric comorbidities, particularly 
anxiety and depression, are highly prevalent among individuals with epilepsy (including those 
with late PTS). Despite their already high prevalence in individuals with epilepsy, research 
shows these psychiatric disorders are underdiagnosed183. Furthermore, presence of multiple 
psychiatric comorbidities that may go untreated in individuals with epilepsy can significantly 
decrease health-related quality of life184.  
 Multiple psychiatric comorbidities are also prevalent following TBI and are associated 
with decreased quality of life measures140; 185; 186. Therefore, individuals with late PTS are likely 
at an even greater risk of psychiatric and quality of life comorbidities compared to those with 
TBI or epilepsy alone. Further research is required to more closely examine the risk of 
psychiatric comorbidities and poor quality of life outcomes for individuals with late PTS, paying 
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particular attention to the effect of AEDs and psychiatric medications. However, allocating 
additional resources now toward services for those at high-risk and already diagnosed with late 
PTS could greatly benefit affected individuals by improving social support and potentially 
reducing negative psychosocial effects associated with epilepsy.   
 Late PTS, its associated comorbidities, and need for frequent and specialized healthcare 
utilization pose a significant quality of life, socioeconomic, and health care burden on 
individuals with this condition. The work presented adds to the growing body of PTS literature 
by characterizing incidence, developing prognostic models, and identifying novel genetic 
variation associated with PTS. Classifying high-risk populations could facilitate future research 
on the effectiveness of tiered prophylaxis and novel pharmacological interventions. Ultimately, 
recognition of an individual’s risk for PTS may help patients and caregivers by providing 
education regarding their risk, signs of seizure activity, and connecting them to social support as 
well as proper medical resources for monitoring, prophylaxis and treatment. These actions may 
help to improve long-term outcomes in individuals at high risk for PTS.  
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